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Abstract 
Cardiovascular disease is a worldwide problem as the number one cause of 
death and disease. Although improvements in pharmaceutical and surgical 
interventions have increased patient survival post infarction, approximately 
half those that recover have a progress to congestive heart failure. 
Stem cell therapy is a strategy to improve functional recovery after 
myocardial injury. Many early phase clinical trials have been conducted 
throughout the world, albeit with variable results. It is postulated that the 
transplanted cells are not retained within the peri-infarct region and either 
apoptose or migrate to the spleen.  
This thesis aims to understand the functional characteristics of bone marrow 
mononuclear cells (BM-MNC) and Mesenchymal Stem Cells to characterise 
their adhesion and migration responses that are essential for successful cell 
retention. 
In vitro model assays were developed to mimic the physiological environment 
of the peri-infarct region using hypoxic conditions and fibronectin, an 
extracellular matrix that is highly upregulated in the infarct region.      
In vivo rat studies have shown Stromal Derived Factor-1 (SDF-1) stimulated 
MSCs improved cardiac function post infarction. In this study SDF-1 
stimulation had no effect on the in-vitro adhesion and chemotaxis of MSCs 
and BM-MNCs. Both cell types had significantly decreased adhesion to 
fibronectin in hypoxic conditions 
To investigate the importance of Neuropilin-1 (NRP1) MSCs were knockdown 
for the protein. NRP1 knocked down MSCs had significantly decreased 
adhesion to fibronectin, chemotaxis to PDGF-AA, and interactions with 
endothelial cells. Expression of NRP1 was enhanced by basic fibroblast 
growth factor that enhanced adhesion in hypoxic conditions and increased 
vascular endothelial growth factor release. 
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Chapter 1 – Introduction 
Cardiovascular disease (CVD) is the number one cause of mortality and 
morbidity in the world (WHO, 2005). CVD is a huge burden on the UK 
economy, costing over £30.7 billion a year (Allender, 2008). If treatment is 
not improved it is predicted by 2030, almost 24 million people will die per 
year from CVDs worldwide, with heart disease being the most predominant 
form of CVD.  In the UK alone approximately 150,000 people a year have a 
myocardial infarction (MI; Heart attack)(BHF, 2008). In the past half century, 
mortality rates from acute myocardial infarction (AMI) have decreased due to 
advances and breakthroughs in pharmacological therapies and surgical 
intervention, leading to >90% survival rate 30 days post-MI (White et al., 
2005). However, injured myocardium is never fully repaired and the patient is 
likely to develop congestive heart failure, the leading cause of mortality in 
post-MI patients that have increased in number as more survive. This is 
because after an AMI the ischemic region of the heart becomes necrotic and 
non-contractile collagenous scar tissue is deposited, so the heart cannot 
pump as efficiently. With a region of the heart non-viable, the surrounding 
myocardium becomes overburdened, and so the cardiac function 
deteriorates. 
Adult stem cells represent a new potential therapeutic in cardiovascular 
medicine. Developments in stem cell biology have resulted in their 
identification as potential candidates for the treatment of heart disease. 
Numerous studies, in animal and human, have used cell populations loosely 
termed bone marrow stem cells (BMSC) for chronic heart failure and acute 
MI indicating a significant therapeutic benefit. Despite these studies the 
precise mechanism of action remains elusive. Conflicting reports suggest 
models of either paracrine, immunomodulatory, or regenerative paradigm.  
BMSCs are a very broad range of cells including endothelial progenitor, 
mesenchymal multipotent adult progentior and haemopoeitc stem cells. 
Although there have been numerous clinical trials evaluating their collective 
potential, few trials have used individual populations. However, there have 
been numerous animal studies selectively separating the populations for 
cardiac repair. 
This review will concentrate on the use of bone marrow stem cells in AMI, 
while acknowledging their use in chronic heart disease. It will focus on the 
recruitment of BMSCs to the infarct region, and discuss the potential 
mechanism of the derived benefits. By utilising this knowledge there is great 
scope for translating sound basic science to improve the modest effects of 
BMSC achieved in clinical trials which one day may become a recognized 
therapy.  
 
1. The Heart and Myocardial Infarction  
1.1 The Heart 
The heart is a muscular organ, composed of cardiac muscle tissue that 
pumps blood to the lungs and the rest of the body. The heart consists of 4 
main chambers, 2 atrium and 2 ventricles. The atria receive blood coming 
into the heart and deliver blood to the ventricles. The right atrium receives 
deoxygenated blood and delivers it to the right ventricle to be pumped to the 
lungs. The left side receives oxygenated blood and pumps it to the rest of the 
body. Therefore the left ventricle muscle wall is much thicker than that of the 
right ventricle. While the heart delivers blood to the rest of the body, it is 
supplied with oxygenated blood via the coronary arteries that ensure 
adequate delivery to the myocardium. The 3 main coronary arteries are 2 on 
the left and  one on the right that originate from the aorta (Katz, 2005). 
The heart wall consists of the epicardium, the membrane that covers the 
heart, the thick muscular layer of the myocardium, and the endocardium, the 
inner lining. These layers are contained within a double walled sac called the 
pericardium (Figure 1). 
 
Figure 1 - Anatomy of the heart (Carter, 2012) 
The myocardium comprises predominantly of cardiomyocytes that pump the 
blood round the body. The myocardium is enveloped by the endocardium 
and the epicardium 
Contraction of the muscle cells, cardiomyocytes (CM), is synchronised to 
ensure coordinated ventricular contraction. In order to do this the 
cardiomyocytes are interconnected by contiguous cytoplasmic bridges. 
Contraction of the CM is generated by an action potential in the pacemaker 
cells in the sino-atrial node. This is transmitted throughout the atria through 
the A-V node, to initiate a contraction. Simultaneously, this transmission 
causes the excitation of the atrio-ventricular node that spreads the excitation 
to the ventricles causing a coordinated ventricular contraction. This 
mechanism is repeated allowing a rhythmic wave like pumping action 
allowing blood to be received in and efficiently pumped out (Katz, 2005). 
Although, myocytes account for over 90% of the myocardium volume, due to 
their comparative large size they only comprise of a quarter of the cells in the 
heart. The rest consists of fibroblasts and endothelial cells making up the 
dense capillary network. The cardiomyocytes consist of the cell membrane, 
sarcolemma, and T tubules for impulse conduction, and the sarcoplasmic 
reticulum, a calcium reservoir for contraction. The contractile unit is an 
arrangement of thick filaments composed of myosin and thin filaments 
containing actin that makes up the sarcomere. Sarcomeres also contain 
troponin and tropomyosin. The usual striated appearance of CMs is due to 
arrays of sarcomeres in series (Figure 2). This arrangement allows 
contraction of the cardiac muscle by sliding of the actin filaments between the 
myosin, toward the centre of each sarcomere. Compared to skeletal muscle 
cells, cardiac muscle contains a substantial amount of mitochondria 
emphasising consistently high metabolic requirement. Therefore, if a region 
of myocardium is deprived of oxygen for even a short period, severe 
consequences that can ensue, leading to loss of cardiac function or death. 
 Figure 2: Striated appearance of cardiomyocytes in the 
myocardium(Skyschally et al., 2008)  
Myocardial Infarction commonly occurs in patients with Coronary Heart 
Disease (CHD), when sudden rupture of a pre-existing atherosclerotic 
plaque occludes a coronary artery.  There is often no warning and for 
approximately 50% of CHD cases, myocardial infarction is the first 
manifestation of the disease. The underlying pathophysiology of CHD is 
accumulation of atherosclerotic plaques within the walls of the coronary 
arteries. The formation of this plaque can involve inflammation, often 
initiated by dyslipidemia or hypertension that triggers enhanced monocyte 
recruitment into the arterial wall (Jefferson and Topol, 2005). Upon 
attachment to the endothelium these monocytes differentiate into 
macrophages expressing surface scavenger receptors. The receptors 
enable the macrophages to uptake oxidised low density lipoprotein (LDL) 
by endocytosis.  Eventually foam cells are formed, and cholesterol is 
deposited in the plaque. When the foam cells die their constituents are 
released attracting more macrophages increasing the plaque burden. The 
genesis of MI is caused by the fissure of the maturing plaque, allowing the 
constituents to exude into circulation, and an acute thrombus is formed 
(Jefferson et al 2005).  This rupture leads to the occlusion of a coronary 
artery, blocking bloody supply, rendering the affected area of the heart 
ischemic. (Figure 3) 
 
Figure 3 - Occlusion of a coronary artery is the cause of myocardial 
infarction  
1 - occlusion of left coronary artery due to ruptured athersclerotic plaque, 
large area left ischemic ; 2 - An occlusion lower down, less myocardium is 
affected-; LCA – Left coronary artery; RCA – Right coronary artery 
(Jefferson et al 2005) 
 
When cardiac tissue is deprived of oxygen the myocardium becomes 
hypoxic triggering an ischemic cascade causing necrosis.  Necrosis 
spreads from the centre to the border of the occluded vascular region 
2
1 
1 1 
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(Skyschally et al., 2008). The final result is a non-contractile collagen 
scar. The size of the infarct region depends on several factors including 
residual blood flow through the collaterals during ischemia, heart rate and 
the location of the perfusion area distal to the occlusion. The final infarct 
size develops over several hours. Therefore, as long as the collateral 
blood flow is sufficient, some ischemic myocardium can potentially be 
rescued during reperfusion (Schaper and Schaper, 1988). Coronary 
collateral blood flow is vital for response to acute and chronic 
ischemia(Hakimzadeh et al., 2014). Collateral vessels result from 
arteriogenesis of pre-exisiting intercoronary anastomoses (Heil and 
Schaper, 2004). Arteriogenesis is promoted by the fluid shear stress 
detected by the vascular endothelium that causes the enlargement of 
collateral vessels through growth and proliferation. The endothelium 
releases several chemokines that attract monocytes that mature to 
macrophages. The macrophages secrete other growth factors and 
cytokines such as basic fibroblast growth factor and TNFα aswell as 
matrix metalloproteinases that break down the surrounding extracellular 
matrix allowing space for the growing vessel (Fung and Helisch, 2012). 
These vessels can grow to the extent that they take over the role of the 
occluded artery (van Oostrom et al., 2008). In patients with adequate 
collateral flow, an acute coronary occlusion ischemia may not occur.  
In rodents, the time scales are different, with the final infarct size in 
rodents with high heart rate and low collateral blood flow being reached 
after 30 minutes (Verdouw et al., 1998). This is important to factor in 
when assessing data from mouse and rat MI models 
1.1.1 Inflammatory response 
 
Inflammation, in addition to being a contributing factor to the initiaton of 
MI, has a major impact post-MI. During myocardial ischemia mitochondria 
from the cardiomyocytes are extruded through breaks in the sarcolemma 
and unfold, releasing membrane fragments rich in cardiolipin and protein. 
These fragments bind to C1 triggering the complement inflammatory 
cascade (Frangogiannis, 2008). Complement activation is followed by 
neutrophil and monocyte recruitment to the infarct area (Rossen et al., 
1994), 
After inflammatory induction, neutrophils extravasate into extravascular 
tissue in response to chemotactic stimuli (Figure 4). Those 
cardiomyocytes expressing ICAM-1 bind neutrophils, via the Mac-
1(CD11b/CD18)/ICAM-1(CD54) interaction. Expression of ICAM-1 is 
known to be upregulated after MI following complement binding (Niessen 
et al., 1999). This adhesion triggers the neutrophil respiratory burst that is 
cytotoxic to the adhered cell. The extent of myocardial injury is neutrophil 
dependant as neutrophils become entrapped in the microvasculature 
preventing reperfusion.  It has been demonstrated that depletion of 
neutrophils in animal models undergoing reperfused myocardial infarction 
led to a decrease in infarct size (Kin et al., 2006).  
 
  
 
 
 
 
 
Figure 4 Invasion of ischemic myocardium by neutrophils (Kin et al., 
2006). 
White arrows - cardiomyocytes; Green - neutrophils 
 
Macrophages are heavily involved post-MI, having an active role in 
inflammation, scar formation and scar remodelling (Lambert et al., 2008). 
Signals from resident cells and neutrophils account for the monocyte 
migration towards the injured myocardium, especially the chemokines 
monocyte chemoattractant protein (MCP-1;CCL2) and TNF-α. This infiltration 
occurs predominantly after reperfusion. Monocytes are postulated to be 
recruited from the spleen as post-mortum analysis has shown accumulation 
of monocytes in the myocardium correlating with depletion in the spleen (van 
der Laan et al., 2014).  
Once the monocytes adhere to the ECM the macrophage conversion is 
triggered (Lambert et al., 2008). The activation of macrophages is divided 
into two groups: proinflammatory (M1) and anti-inflammatory (M2). M2 
macrophages promote angiogenesis and ECM reconstruction, whereas M1 
macrophages initiate ECM destruction after induction by lipopolysaccaride. 
After MI macrophages are activated initially via the M1 pathway and then by 
the M2 pathway. The M2 macrophages are induced by glucocorticoids and 
ingest apoptotic neutrophils and necrotic myocytes, facilitating the wound 
healing process (Luikart et al., 2006). These M2 macrophages are derived 
from mature M1 macrophages by treatment with interleukin 4 (IL-4) or IL -13 
(Ho and Sly, 2009). M2 macrophages release TGFβ1 initiating collagen 
release from the fibroblasts in the ischemic myocardium. This inflammatory 
response improves tissue repair, and  several studies have demonstrated 
that stimulating macrophages with macrophage- colony stimulating factor (M-
CSF) results in improved cardiac function (Okazaki et al., 2007). 
Furthermore, Yano et al showed that macrophage depletion leads to 
impaired wound healing, highlighting the importance of the macrophage 
(Yano et al., 2006). 
In addition to monocytes, CD34+ mononuclear cells are mobilised in 
response to myocardial infarction although their role in myocardial 
regeneration has yet to be established (Theiss et al., 2007)  
Additional inflammatory responses are regulated by the complex formation of 
nuclear factor kappa beta (NF-κβ) and Inhibitor of κβ (Iκβ). NF- κβ is a 
protein complex that regulates the transcription of many genes involved in 
proliferation and cell survival particularly in macrophages. Activation of NF- 
κβ is mediated by the release of cytokines and free radicals that are 
predominantly released by mast cells. TNFα is a cytokine implicated in the 
initiation of this cytokine cascade. By knocking down both TNF 1 and 2, 
receptors causes larger infarcts are evident after MI, and increased myocyte 
apoptosis is observed compared to controls (Kurrelmeyer et al., 2000).  
1.1.2 Endogenous stem cell repair 
 
The heart was long assumed to be post-mitotic containing purely terminally 
differentiated cells rendering the post-natal heart unable to regenerate after 
damaged. However, recent evidence has identified an endogenous reserve 
of cardiac stem cells (CSCs) and early committed cells (ECCs) (Urbanek et 
al., 2005). These cells are referred to as cardiac side populations (CSP) and 
are found in both the atria and ventricles. They are able to give rise most cell 
types in the heart including cardiomyocytes, fibroblasts, endothelial cells and 
smooth muscle cells (Kajstura et al., 2008). Under normal conditions, 
cardiomyocytes and fibroblasts have a very low turnover, so only a small 
number of CSPs are required. This is contrary to tissues and organs such as 
the gut and oral mucosa that both have a higher proportion of stem cells due 
to high cell turnover. CSPs are classified into subtypes based on their 
surface marker characterisation eg. Sca-1+ and c-kit+, while ATP binding 
cassette subfamily group 2 (Abcg2), a has been identified as a marker for all 
these CSPs (Meissner et al., 2006). These cells have been identified in the 
ischemic border zone following MI, indicating a cellular response to cardiac 
injury by these populations but it is not significant to fully repair the heart after 
MI. The reduced vascular perfusion to the infarct area may reduce the 
activation of resident CSP cells. However, in vivo studies have shown that 
injection of CSPs into infarcted myocardium increases ventricular function 
and regenerates necrotic tissue (Kajstura et al., 2008). 
1.2 Burden of myocardial infarction 
 
After the inflammatory phase granulation tissue is established, and cardiac 
fibroblasts proliferate. These cells migrate out of the granulation region 
leaving a matrix rich in collagen. The apoptotic cells lead to expression of 
anti-inflammatory cytokines and TGFβ, which initiates the transition from 
inflammation to fibrosis (Frantz et al., 2009). Ventricular remodelling occurs 
that leads to the expansion of the initial infarct area and fibrous tissue 
replacing cardiomyocytes in the ventricular wall (Kocher et al., 2001).  The 
collagen scar leaves a burden on remaining viable cardiomyocytes in the 
surrounding margins, leaving them over-stretched. After an AMI, if the patient 
survives, the heart is permanently damaged. They are now susceptible to 
further cardiac events such as ventricular fibrillation and ventricular 
tachycardia. The scar region impairs normal cardiac function, and the infarct 
area could extend as cardiac output and blood pressure fall leading to further 
coronary ischemia. The tightly woven collagen has high tensile strength and 
prevents contraction, hence reducing contractile ability and cardiac output. 
The cardiomyocytes surrounding the infarct region are continually lost after 
the MI, increasing the risk of heart failure.  
1.3 Current treatment 
Current pharmaceutical interventions aim to reduce burden on the heart by 
regulating parameters such as blood pressure and heart rate. However, they 
are not regenerate and do not aid in restoration of damaged tissue or 
stimulation of dormant cardiomyocytes. Immediately after MI, aspirin and an 
anti thrombyltic, such alteplase, are administered to prevent clot build up and 
enhance reperfusion to the ischemic region (Chua et al., 2005). Other acute 
interventions include percutaneous coronary intervention (PCI), a non-
surgical intervention that involves widening the coronary artery via the 
insertion of a balloon catheter to dilate the artery from within. A metallic stent 
can then be inserted once the artery has been dilated (Smith et al., 2006). 
Following MI the patient is given multiple medicines, including aspirin, an 
angiotensin II converting enzyme inhibitor, a statin (3-hydroxy-3-methyl-
glutaryl-CoA reductase inhibitor) and a beta antagonist.  
BMSCs have the potential to overcome, or at least alleviate, this long term 
requirement for medication. Although clinical trials have been conducted 
using BMSCs, clarification of the mechanism of action is required to optimise 
the therapeutic response.  
 
2. Bone Marrow Stem Cell trials for cardiac repair 
Stem cell populations, by definition, can undergo both self –renewal and 
differentiation into at least one functional cell population. Observations that 
bone marrow derived cells can differentiate along the myogenic lineage have 
promoted researchers to investigate the potential benefits of these cells 
following MI. Promising results from animal studies have led to the initiation 
of phase I and II trials for use of BMSCs in human. So far, numerous trials 
have been performed and published on the transplantation of BMSC. Orlic 
and colleagues pioneered the first trial in mouse showing that cells from the 
bone marrow could regenerate infarct myocardium (Orlic et al., 2001). 
However, despite initial promise, subsequent trials have failed to significantly 
build on this, and benefits reported in animal studies have not yet been fully 
translated to human benefit as there have been few phase III trials. Current 
data from trials suggests that patients most likely to derive benefit from bone 
marrow stem cells are those with large infarct and substantially reduced left 
ventricular ejection fraction (LVEF) (Drexler and Wollert, 2009). LVEF is 
commonly used as an immediate measure of clinical outcome and represents 
the fraction of blood pumped out of the left ventricle, calculated by the 
difference between end-diastolic and end-systolic volumes, and the stroke 
volume (SV), divided:  
 
Most of the following trials used autologous bone marrow cells. By using 
autologous cells, the potential of rejection is bypassed, as allogeneic cells 
risk graft versus host disease (GvHD) for which the patient would have to be 
immunosuppressed (Wolf et al., 2009). However, as a longer term aim, 
allogenic cells are likely more desirable due to the potential “off the shelf” 
availability they promise 
2.1.1 Clinical trials 
Several phase I and II trials have investigated the effects of BMSC for 
cardiac repair, with LVEF the most common endpoint. The TOPCARE-AMI 
trial was one of the first randomised clinical trials using progenitor cells in 
AMI (Schachinger et al., 2004). This trial compared the use of autologous 
BMSC against circulating blood progenitor cells administered 5 days after 
percutaneous coronary intervention (PCI). Both groups had an increased in 
LVEF and increased myocardial viability in the infarct zone, however there 
was not an appropriate control group to compare this to. There were no 
significant differences between the two cell populations used. However, the 
trial did highlight the potential of progenitor cell therapy in AMI with sustained 
improvement in cardiac function over 5 years (Yousef et al., 2009). 
In the BOOST study, although LVEF was significantly improved by 6% 
compared to controls after 6 months (the primary end point), this was not 
sustained over 18 months. Although again appropriate placebo controls were 
not used. The trial investigated use of autologous BMSC in patients 5 days 
after MI. The increased LVEF after 6 months was associated with 
improvement in systolic wall motion  (Wollert et al., 2004).  After 18 months 
initial improvements in LVEF were not sustained.  
The REPAIR-AMI trial investigated the infusion of basement membrane 
derived mononuclear cells 4 days after PCI. Their results indicated slight 
improvement in LVEF after 4 months that was sustained over 12 months, 
with mortality benefit observed (Marenzi and Bartorelli, 2007).  These trials 
used a heterogenous population of cells, so the precise subset of clinically 
advantageous cells is not known. The REGENT trial, by Tendera and 
colleagues, addressed this issue by investigating CD34+/CXCR4+ 
mononuclear BMC comparing to to unfractionated mononuclear BMC as a 
reference point (Tendera et al., 2009). However, no significant difference was 
observed between the groups, which both showed an improvement of ~3% in 
LVEF. Despite these results, many trials have shown this therapy to be safe.  
The MAGIC Cell trial compared the administration of with Granulocyte – 
colony stimulating factor (G-CSF) alone versus G-CSF and BMSC. They 
found that the patients treated with G-CSF and BMSC had significantly 
greater improvement in LVEF after 6 months than G-CSF alone(Kang et al., 
2007). This indicates that mobilisation of endogenous stem cells by G-CSF 
alone is not adequate enough to have a therapeutic consequence. G-CSF is 
regularly use in clinical practise for bone marrow transplantation, as it 
stimulates the bone marrow to produce granulocytes and stem cells to be 
released into the blood. The follow up to MAGIC Cell-3-DES trial involved a 
larger amount of patients, and reported improvements in LVEF were reported 
after patients with AMI were administered G-CSF followed by intracoronary 
injection of mobilised BMSCs. Another larger trial of 50 patients reported the 
similar improvements in LVEF after 6 months following after injection of 
BMSC mobilised by G-CSF (Steinwender et al., 2006).  
The Cochrane review for ‘Stem cell treatment for acute myocardial infarction’ 
produced the most comprehensive analysis of randomised controlled trials to 
date (Martin-Rendon et al., 2008). Their main results, from 1765 patients, 
showed a large amount of heterogeneity between studies but overall 
moderate improvements in heart functions were significant both short and 
long term (Martin-Rendon et al., 2008). 
The BALANCE study, treating 62 patients with BMSCs after AMI and 62 
control. This included a long term follow up for all patients after 5 years. 
Results showed an increase in contractility in the infarcted zone (Yousef et 
al., 2009). Most importantly, mortality was decreased and significantly 
augmented exercise capacity compared to the control group. 
However, use of BMSCs for ischemic heart disease (IHD) has produced 
indifferent results. The FOCUS-CCTRN trial demonstrated no significant 
change in left ventricular end systolic volume or clinical improvement 
compared to placebo groups. This is in contrast to several meta-analyses 
that identify transplantation as favourable for IHD (Clifford et al., 2013). It is 
worth noting that non-publication of negative results hinders a true 
comparison (Ioannidis (Ioannidis, 2005) 
Most studies have failed to detect BMCs in the myocardium 3 weeks after 
infusion, despite the maintenance of hemodynamic and anatomical 
improvement (Freyman et al., 2006b; Hale et al., 2008). Approximately 90% 
of transplanted cells die shortly after transplantation as a result of physical 
stress. A consensus on the optimal delivery method and timing of 
administration is desperately needed.   
Use of mesenchymal stromal cells have only been used in a few published 
clinical trials, the majority of which are safety studies. The POSEIDON trial 
investigated the use of allogenic and autologous bone marrow derived MSCs 
in patients with ischemic cardiomyopathy Results from this study 
demonstrate an encouraging safety profile, with improvements in quality of 
life, and NYHA classification indicated functional improvement (Hare et al., 
2012). However, the results of this trial are limited as there was no placebo 
arm included and there were only 5 patients in each experimental group. 
The safety study for Prochymal, the Osiris MSC product, was shown to be 
safe in 53 patients after AMI via intravenous infusion.   After 6 months LVEF 
and pulmonary function were significantly improved in hMSC treated versus 
placebo treated.  
Yang et al chose a different transplantation approach, with delivery via a non-
infarct artery to repair AMI. Results after 6 months showed increased cardiac 
function and myocardial infusion. While no major incidences of adverse 
events following transplantation of MSCs for cardiac repair have been 
reported  
2.1.2 Trial limitations 
These clinical trials are incomparable as relevant variables, such as method 
of cell delivery, site of delivery, primary outcome, condition treated and timing 
of administration, are rarely consistent from study to study. Variability 
between different cohorts of patients can affect the end outcome too (Martin-
Rendon et al., 2008). For instance delivery of cells via intravenous injection 
can be especially problematic in patients with poor circulation. Therefore, 
even before taking into account any other variable, results obtained will be 
largely affected.  
Unlike animal studies it is difficult to track cellular differentiation after 
transplantation. Therefore, the mechanism of action remains elusive, and is 
likely to be multi-factorial considering the distinct cell lineages transplanted. 
Characterisation of these cells presents a problem, as even cells from the 
same lineage can have varying cell surface marker expression depending on 
their maturity (George, 2010). Most studies have correlated CD34+ and 
CD133+ expression with angiogenesis and improved cardiac function. 
Derivation of specific cell types depending on their functionality is required. 
Regardless of the cell populations used, the optimal number of cells 
delivered is unclear. Nearly all clinical trials use a different amount ranging 
from 1 x107 to 5 x 109, a 500 fold difference (Bartunek et al., 2007; Tatsumi 
et al., 2007). 
Additionally, LVEF might not be an appropriate end point as it can often 
underestimate the therapeutic benefit to patients. Even very modest 
increases in LVEF can result in long term positive clinical outcomes. This has 
been addressed by the ASTAMI trial that accessed exercise time over a short 
and long period of time after transplantation to LVEF evaluation (Beitnes et 
al., 2009). They established significant improvements in BMSC patients. 
Another Phase II trial currently underway, REGENERATE-AMI, will access 
the patients Quality of Life 6 months and 1 year after the procedure 
(Hamshere et al., 2014; Yeo and Mathur, 2009). 
3. Bone Marrow cell populations for myocardial repair 
Although progenitor cells are recruited from the bone marrow to site of 
cardiac injury, endogenous reserves do not provide a critical mass capable of 
repair after MI. The bone marrow contains a variety progenitor and 
endothelial subsets. Subpopulations that may have the potential to be used 
to repair injured myocardium include: endothelial progenitor cells (EPC), 
mesenchymal stromal cells (MSC), and haematpoetic stem cells (HSC). 
Although clinical trials have yet to incorporate a selected population of cells 
from bone marrow, several animal studies have detailed their individual 
capability.  
3.1.1 Endothelial Progenitor Cells 
EPCs arise from a multipotent cell called a hemangioblast and are mobilised 
from the bone marrow in response to cytokines or ischemia (Penn and 
Mangi, 2008). EPCs have been shown to increase the capillary density and 
protect against cardiomyocyte apoptosis after systemic injection in rats with 
cardiac ischemia (Penn and Mangi, 2008). They facilitate neovascularisation 
by differentiating into endothelial cells and have been shown to promote ex 
vivo neoangiogenesis that would rescue tissue from ischemia. (Urayama et 
al., 2008). EPCs can contribute to neoangiogenesis by incorporating to the 
endothelium of small vessels in the border zone of the infarct. Although they 
have been shown to transdifferentiate into functionally activate 
cardiomyocytes in vitro this ability has not been reproduced in vivo (Badorff 
et al., 2003). 
EPCs do not have an exclusive cell marker, rather there are several markers 
that identify the EPC population, including CD133, CD34 and vascular growth 
factor receptor 2 (VEGFR-2 or KDR). However, there is controversy over 
definition of EPCs by these surface markers as they are expressed in a wide 
range of cell types. CD34 is expressed on mesenchymal and epithelial cells, 
and KDR are also widely expressed on a number of blood and endothelial 
cells (Hirschi et al., 2008) (Peichev et al., 2000). According to Yoder, EPCs 
should be defined by their function as circulating cells that have proliferative 
potential and can differentiate endothelial lineage. They also should have 
ability to form lumenised capillary-like tubes in vitro and ability to form stable 
human blood vessels when implanted into tissues (Yoder, 2012).       .  
For culture and expansion to clinically relevant EPCs can be isolated into 2 
different subtypes. Either ‘early EPCs’ or ‘late outgrowth EPCs’ as they 
appear after a prolonged culture period forming growing in colonies (Navarro-
Sobrino et al., 2013). Early EPCs are obtained from peripheral blood 
mononuclear cells that are seeded onto fibronectin for 4 days in VEGF 
containing medium, and are CD45, CD14 and CD11b+ akin to a 
haemopoetic lineage (Fadini et al., 2012). Late outgrowth EPCs have a 
longer term ability to proliferate and express more endothelial markers such 
as CD133(Thill et al., 2008). Different subpopulations of EPCs are likely to 
have a variety of functions. Those expressing CD14 and CD45 may facilitate 
neoangiogenesis by release of angiogenic factors (Rehman et al., 2003), 
whereas, CD133 positive cells have higher specifity for an immature cell 
type, giving rise to greater proliferative potential.  
In clinical trials EPCs have been quantified as CD34+/VEGFR2+ or 
CD34+/VEGFR2+/CD133+. However, cells expressing these surface marker 
expression are not real endothelial progenitors but instead monocytic 
progenitors that have angiogenic potential (Rehman et al., 2003). 
Ziegelhoffer et al concluded that EPCs do not incorporate into vessel walls 
but support the formation of new vessels by release of growth factors and 
cytokines acting as perivascular cells (Ziegelhoeffer et al., 2004). 
Lack of consensus of what defines an EPC has restricted the translation into 
clinical practice and remains a work in progress in comparison to other cell 
populations in the bone marrow (Fadini et al., 2012). 
 
3.1.2 Mesenchymal stromal cells 
Mesenschymal stromal cells are precursors of non-haemaopoietic tissues 
that exhibit low immunogenicity.  MSCs account for 0.001 – 0.01% of all cells 
isolated from the bone marrow (Pittenger et al., 1999),. They are an 
endogenous population that has the potential to differentiate into a variety of 
cell types of the mesoderm, endoderm, and ectoderm. They can be 
distinguished from other bone marrow cells due to their adherence to cell 
culture dishes.  
MSCs are characterised by their expression markers as they are positive for 
Sca1+, CD44, CD73, CD90, CD105, CD166 and STRO-1, but do not express 
typical markers of HSC such as CD45, CD34 and CD14 (Brooke et al., 
2008). Also they have been shown to acquire markers of cardiomyocytes and 
mediate connections via by connexion 43 gap junctions (Novotny et al., 
2008). However, these defining characteristics are becoming outdated as 
recent studies have shown fibroblasts and perivascular cells express the 
same markers and have similar gene expression profiles (Covas et al., 
2008b),. The International Committee of Cellular Therapy (ISCT) has 
reiterated the need to quantify the functional potency of these cells using 
standardised assays (Krampera et al., 2013) 
Treatment of ischemic hearts with MSCs has led to increased vascular 
density (Silva et al., 2005). MSCs may contribute to early angiogenesis by 
promoting endothelial cell migration and proliferation through paracrine 
effects. In vitro studies have shown MSCs to function as perivascular 
precursor cells stabilising venous arterial cells (Duffy et al., 2009). They can 
also contribute towards later stages of angiogenesis in vessel stabilisation. 
Other In vitro studies have observed that MSCs promote EC-EC interactions 
in non-contact co-culture decreasing endothelial monolayer permeability (Pati 
et al., 2011), 
Studies that have monitored the final location of MSCs to determine 
migratory paths after transplantation showed that <5% are actually found in 
the heart, with most becoming immobilised in the lung (Wang et al., 2011). 
However despite this they still produce beneficial responses in MI patients 
(Lee et al., 2009a) These trapped MSCs have been shown to express a 28 
fold increase in TNF stimulated gene 6 protein (TSG-6) (Lee et al., 2009a). 
Immunomodulatory factor TSG-6 inhibits neutrophil filtration and protease 
production. It does so by entering the circulation, reducing the inflammation 
caused after ischemic injury. By reducing the neutrophil invasion, their 
negative impact is reduced and hence so is the size of the final infarct. This 
observation suggests a non-regenerative immunomodulatroy role for cells.   
The ability of MSCs to adhere and expand on tissue culture plastics enables 
their isolation from bone marrow and under set in vitro conditions they can 
differentiate into cardiomyocytes, characterised by their expression of cardiac 
troponin T, and phospholamban (Song et al., 2010). They are also able to 
differentiate into endothelial cells after administration of vascular endothelial 
growth factor (VEGF) and 5-aziothioprim (5AZT).  Both of these differential 
lineages could be exploited for therapeutic benefit for cardiac repair, and 
observations in pig, mouse and rat following MI suggesting consistency is 
conserved between the species (Shake et al., 2002). However, in a swine 
model allogenic MSCs only transiently increased cardiac function despite 
contributing to neovascularisation and myogenesis (Shake et al., 2002). 
Few studies have accessed the signalling pathways activated, and many 
have chosen to identify factors released. For instance, Canonical Wnt 
signaling is retains self renewal and represents a stem cell niche signal. 
When activated this can cause MSC lineage commitment, whereas 
proliferation is driven when inhibited. MSCs overexpressing a Wnt modulator, 
secreted frizzled-related-protein 2 (sFRP2), increased angiogenesis, 
enhanced engraftment and significantly reduced final infarct size when 
transplanted into a rat infarcted heart (Alfaro et al., 2008). 
3.1.3 Haematopoietic Stem cells 
HSCs found in adult bone marrow are multipotent stem cells that can 
produce cells of the lymphoid and myeloid lineages (Yilmaz et al., 2006). 
They are already routinely exploited in clinical practice for bone marrow 
transplants. They are characteristically small size and lack lineage markers 
(lin-). However, due to the many subpopulations there are issues with 
characterisation using surface expression markers. For example, CD34 and 
CD38 are commonly expressed in HSCs, but there are some HSCs that are 
CD34- /CD38-. CD34 expression can be used to distinguish between short 
term and long term HSCs, with CD34+ applying to short term, and CD34- 
distinguishing long term HSCs.  Both Lin-CD34+CD38- and Lin-Sca1+ HSCs 
have demonstrated intercellular connections with resident cardiomyocytes 
when intravenously injected (Ishikawa et al., 2006; Orlic et al., 2001). 
However, they have not been shown to differentiate into cardiomyocytes or 
endothelial cells in the infarcted myocardium. 
Mobilisation of these cells is enabled by conditioning with G-CSF (Fu and 
Liesveld, 2000). This increases matrix metalloproteinase-9 (MMP9) and 
several other matrix proteases that cleave adhesion molecules in the bone 
marrow stroma, facilitating mobilisation of not only HSCs but also 
macrophages and monocytes into the peripheral blood. G-CSF also disrupts 
the SDF-1/CXCR4 axis mobilising the HSCs enabling them to exit the bone 
marrow. SDF-1 corresponds with it’s receptor CXCR4, which enhances 
adhesion from blood to endothelium (Brooke et al., 2008). Flt3 ligand has 
also been shown to facilitate interfere with the CXCR4 signally pathway 
facilitating the mobilisation of HSCs (Fukuda et al., 2005)  
There are differences between surface marker expression in mouse and 
human HSCs. As animal studies are commonly used the differences must be 
acknowledged when translating into clinical practise. These differences are 
presented in Table 1 
 
 
Table 1  Species differences in surface marker expression of 
HSCs 
Human Mouse 
CD34+ CD34
-/lo 
CD59+ SCA-1+ 
Thy/CD90+ Thy1.1+/lo 
CD38-/lo CD38+ 
c-kit/CD117+ C-kit+ 
Lin- Lin- 
 
From studies using murine MI models there is no clear evidence that to drive 
cardiac regeneration HSCs differentiate into cardiomyocytes or endothelial 
cells (Balsam et al., 2004; Murry et al., 2004).   
A selected cell population has yet to be identified that can home to the 
injured myocardium, participate in vasculogeneis, and survive long term after 
engraftment. It could be that more than one cell subset is required, as use of 
more than one subpopulation may produce additional or synergistic effects. 
For instance, the engraftment of HSCs is facilitated when co-transplanted 
with MSCs. In addition, the immunomodulatroy effect of MSCs decreases the 
incidence of an immune response (Lu et al., 2006).  To establish interactions 
within the ischemic myocardium, MSC and HSCs, may use different surface 
adhesion molecules (Ip et al., 2007). This would thereby influence the 
mechanism for homing and trafficking.  
3.2 Preconditioning for optimised therapy 
The main issue with injecting cells either intravenously, 
intramyocardially, or intracoronary, is mass cell loss due to 
apoptosis due to ‘anikosis’ and migration to the liver and spleen 
(Lu et al., 2009).. Improving the survival of transplanted cells is 
imperative Freyman et al, showed that only 0.5% of bone marrow 
cells injected into a mouse infarct heart survived (Freyman et al., 
2006b). While the amount of cells administered is identified as a 
critical factor for cell therapy if only a minute fraction survive, any 
potential benefit is surely negated. A few studies have established 
methods of preconditioning the cells to improve survival and 
cardiac repair (Table 2). Most of these studies have used MSCs, 
due to their ease of isolation and adherence to cell culture dishes 
for ex vivo analysis. 
Table 2 -Improving cell therapy by preconditioning  
Study Modulator Outcome (comparison of treated 
and non-treated groups) 
(Hahn et 
al., 2008) 
FGF-
2,BMP2,IGF-1 
    Apoptosis; infarct size 
    Engraftment; cardiac function 
(Chang et 
al., 2012),  
HSP 70     Cardiac repair; cardiac function 
(Yang et 
al., 2009) 
Simvastatin     Survival 
(Pasha et 
al., 2008) 
SDF-1     Apoptosis 
    Engraftment; differentiation; 
cardiac function 
(Yao et 
al., 2009) 
Lipopolysaccaride     Fibrosis; apoptosis of infarcted 
heart 
    Survival; blood vessel density; 
cardiac function 
(Wang et 
al., 2011) 
Neuropeptide Y     fibrosis 
   differentiation; 
angiomyogenesis; cardiac 
function 
(Wisel et 
al., 2009) 
Trimetazine     Fibrosis 
    LVEF; fractional shortening 
(Guo et 
al., 2008) 
HGF     Angiogenesis; cardiac function 
(Chang et 
al., 2012) 
Hypoxia     Survival;Angiogenesis 
    Fibrosis; apoptosis 
(Ray et 
al., 2008) 
Oestrogen     Fibrosis; remodelling 
 IGF-1 has been shown to reprogram Sca1+ cells for pro-survival signalling 
and cardiomyogenic differentiention. This process is mediated by 
upregulation of connexion 43(Cx-43), that forms intercellular Cx-43 is 
important for cytoprotective function by an antiapoptotic role, preventing 
cytochrome c translocating from the mitochondria to the cytoplasm. 
Engraftment is also increased, as induced Sca1+ cells enhance 
cardiomyogenesis due to colocalisation of cx-43 with myosin and sarcomeric 
actinin representing coupling with exisiting fibers, increasing gap junction 
formation (Lu et al., 2009). Bone marrow cells pre-treated with IGF-1 prior to 
injection into the infarct region where shown to have significantly increased 
survival, as IGF-1 triggers the AKT pathway.  IGF-1 transiently activates the 
PI3K/AKT pathway. Sca+1 cell stem cells are then able to differentiate into 
cardiomyocytes. Enoki et al have shown that this improves survival of 
transplanted MSCs by inhibiting the PI3K pathway(Enoki et al., 2009). 
Transplanted cells are injected into an environment of high stress decreasing 
their viability. When Chang et al preconditioned MSCs with Heat Shock 
Protein 70 (HSP70), a protective protein against stress, these cells where 
transplanted into an infarcted heart producing anti-apoptotic properties and 
increased cell viability. This allowed the treated cells to become integrated 
into the infarcted myocardium (Chang et al., 2009). Results showed an 
increase in microvessel density and overall heart function.  
Another protein found to suppress apoptosis is the cytokine SDF-1. Cells 
preconditioned with SDF-1, when transplanted into an infarcted heart, 
displayed increased cell viability, improved heart function with decreased 
infarct size and fibrosis, while increasing vascular density and cardiac 
differentiation (Pasha et al., 2008).  
 By preconditioning MSCs with lipopolysaccaride (LPS), the efficacy of MSC 
transplantation after myocardial infarction can be enhanced (Yao et al., 
2009). Benefits identified include increased vascular density and cell survival 
rate. The LPS induces VEGF expression and p-AKT induction increasing the 
cardiac function due to enhanced vascularisation.  
An apparent issue with most cytokine preconditioning is that they are not 
currently use in clinical practise, so translation of these into man is a long 
way down the line. However, statins and trimetazidine, 2 established 
medications can overcome this problem as they have similar effects to these 
cytokines. Trimetazidine is an anti-ischemic drug for angina treatment. Hearts 
treated with trimetazidine preconditioned MSCs were found to have a 
significant reduction in fibrosis, and increased cell viability compared to 
normal MSCs transplantation (Wisel et al., 2009). Administration of a 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor, like 
simvastatin, shows great potential in not only increasing survival, initiates 
differentiation, increases angiogenesis, reverses ventricular remodelling and 
reduces infarct size (Yang et al., 2009).  Statins mediate the reduction of 
proinflammatory cytokines and inhibit expression of Bax, an apoptotic 
protein. Inhibition of apoptosis may also be regulated by activation of 
Akt/eNOS (endothelial Nitric Oxide Synthase) pathway (Yang et al., 2009). 
Increasing eNOS production also leads to increased matrix metalloproteinase 
(MMP) 9 that facilitates stem cell mobilisation. This increases 
cardiomyoplasty efficacy and hence improve cardiac function after the MSC 
transplantation. Other agents that prevent apoptosis in this microenvironment 
are cyclosporine A and Lysophosphatidic acid (Liu et al., 2009); (Chen et al., 
2008). 
In addition to increasing transplanted cell survival other experiments have led 
to the initiation of certain pathways within the bone marrow cells. For 
instance, growth hormone production is stimulated in Oestrogen treated bone 
marrow MSCs and EPCs. This caused improve myocardial remodelling when 
injected into an infarcted rat heart, by increasing capillary density  (Ray et al., 
2008), . 
Another study investigated the infusion of Neuropeptide Y showing that it 
directly induces adult cardiomyocyte cell cycle re-rentry and enhances the 
number of differentiated cardiomyocytes from MSC in the infarcted 
myocardium resulting in improved cardiac function, reduced fibrosis and 
increased angiomyogenesis (Wang et al., 2009).   
The desired outcome of these transplanted cells is to have a beneficial effect 
within the ischemic region, and improve cardiac function via various 
mechanisms. However, the microenvironment of the ischemic border zone is 
devoid of oxygen and nutrients causing cell death. It is logical that a 
cytoprotective state needs to be induced. This can be mediated by hypoxia 
preconditioning. By denying the cells oxygen activates the AKT pathway, so 
cell viability and cell cycle is continued (Mangi et al., 2003). Compared to 
controls, hypoxic conditioning enhanced the survival, and angiogenic ability 
of MSCs. 
Preconditioning of BMSCs, according to data from these animal studies 
described, appears a plausible solution to the integral problems and 
variability observed in clinical trials. Increasing cell viability within the infarct 
region is a fundamental factor for this.  
4. Improving cell retention 
4.1 Stem cell homing and migration 
When a myocardial injury occurs signals are released by the cells in the 
damaged myocardium to repair the injured tissue. The underlying mechanism 
by which cells from the BM are recruited to site of injury needs to be fully 
elucidated. Studies with superhealer mice MRL/MpJ (McBrearty et al., 1998) 
that have shown that myocardium can regenerate by scarless healing. These 
mice were found to have 3 fold greater quantity of BM derived cells in the 
heart than non-injured mice or injured WT mice (Heber-Katz et al., 2004). 
This effect has been reproduced in WT mice by engraftment of BM from 
MRL/MpJ mice (Bedelbaeva et al., 2004). The increased efficacy may be due 
to increased homing, trafficking to infarct region, engraftment survival, or a 
variety of these. 
Several chemokines and growth factors are important for cell homing to the 
infarcted region, including insulin growth factor 1 (IGF1), stromal cell derived 
factor 1 (SDF1), monocyte chemoattractant protein 3 (MCP3) and hepatocyte 
growth factor (HGF). The mechanism of recruitment can be exploited for cell 
transplantation to maximise the amount of cells directed to the infarct region 
and ensuring their residence. Preconditioning the BMSC to express specific 
receptors to these paracrine factors has been explored with promising results 
using animal models, as previously described. Ip et al investigated the 
myocardial migration and engraftment of MSC. By preconditioning the cells 
with G-CSF and stem cell factor (SCF) the myocardial repair was enhanced 
and cardiac function was increased (Ip et al., 2007).  They showed that BM-
MSC are dependent on integrin α4β1, α5β1 and CD29 for migration to the 
ischemic myocardium. 
By generating a gene expression profile from the MI heart, chemokines, 
adhesion molecules and cytokines up regulated by injury have been 
identified. After MI SDF-1 expression is dramatically increased, which acts as 
a homing signal to those cells expressing CXCR4 including HSC and MSCs 
from the bone marrow. This expression is present immediately after, and 
persists for several days. SDF-1 also improves vascular density, and 
prolongation of resident SDF1 expression. The SDF-1 gradient is important 
for stem cell recruitment, so maintenance of the gradient is desired. Lee et al 
demonstrated that after BMSC transplantation, SDF-1 levels in the 
myocardium increase (Lee et al., 2009a). Therefore cell therapy generates a 
favourable chemokine gradient for stem cell recruitment into the infarcted 
myocardium. SDF-1 mediated recruitment is dependant on the membrane 
expression levels of CXCR4 receptor. Overexpression of SDF-1 increases 
stem cell homing and engraftment to ischemic regions. This can also be 
endogenously upregulated in the myocardium by endothelial nitric oxide 
synthase (eNOS) derived nitric oxide (NO), promoting migration. While 
increasing the chemokine increases the homing effect, so does upregulation 
of the CXCR4 receptor. IGF-1 can up-regulate this expression of CXCR4 
(Penn and Mangi, 2008),. This leads to greater survival and homing of MSCs, 
and therefore greater improvement of cardiac function through greater 
paracrine factor expression. 
However, SDF-1 is not exclusively expressed in cardiac tissue as it is also 
expressed in the liver and spleen (Zhang et al., 2008). Therefore, 
transplanted BMSCs migrate to these regions aswell. By doing so they are 
eliminated through the pulmonary first pass effect where the cells become 
microembolised. This may reduce the degree of ‘homing’ and account for the 
evidence that only 5 % of transplanted BMSCs are found in the infarct region. 
Surface marker expression can have an effect on micro-embolism given that 
since as MSCs with high expression of podocalyxin (PODXL) and CD49f are 
less prone to form pulmonary embols and increasing numbers are found in 
the heart compared with PODXL-/CD49f- MSCs (Lee et al., 2009b) 
Hypoxia inducible factor 1 (HIF-1) is another cytokine implicated in homing of 
stem cells albeit indirectly. HIF-1 is released in the ischemic myocardium 
casing an increase in VEGF expression that stimulates the migration of EPCs 
(Novotny et al., 2008).  
Once the cells home to the ischemic region, unless they are injected directly 
to the ischemic border zone, migration through the endothelium is imperative. 
Similar to leukocytes, the recruited stem cells enter the extracellular matrix 
from the blood by tethering, adhering, and intergrin rolling along the 
endothelium due to the actions E and P selectin molecules. Integrin β1 has 
also been identified as crucial for the rolling and adhesion in MSCs (Ip et al., 
2007). Migration and homing of MSCs is mediated by integrin β1 via the 
MCP-3-CCR1 and CCR2 axis (Ip et al., 2007). This is distinct from CD34+ 
haematopoietic cells that home via the CXCR4 receptor. This suggests that 
MSCs and HSCs have distinct classes of surface adhesion receptors for 
interactions with either the ECM or resident cells. 
Rolling is instigated by the extracellular expression of P and E selectin on the 
endothelium surface that complements selectin receptors on MSCs. Firm 
adhesion to the endothelial cells is then mediated by VCAM-1 and VLA-4 
expression. For transmigration integrin α4β1 binds to the endothelial VCAM-
1. Migration through the ECM is then mediated by adherence to hyaluronic 
acid by CD44 and is subsequently facilitated by MMP-2 which cleaves a path 
for movement along the chemokine gradient (Steingen et al., 2008). 
4.2 Adhesion 
Once the cells have been able to home to the infarct region, it is vital for the 
BMCs to attach and remain within this region. When cells are transplanted 
into the heart if they do not engraft anoikis will occur (Michel, 2003),. Anikosis 
is programmed cell death that occurs due to lack of attachment, or loss of 
contact with, ECM proteins. For cells to engraft, they need matrix support. If 
there is inadequate interaction between glycoproteins of the extracellular 
matrix (ECM) and the cells, apoptosis will occur. This interaction ensures the 
survival of the endogenous adhered differentiated cells within the heart. 
Therefore, adhesion is required involving integrins, connexins and adherins. 
Integrins are an important adhesion mediators and attachment via integrins 
causes tensegrity, a tensile stress within the cell, preventing apoptosis (Song 
et al., 2007). However, if cells do not attach the opposite will occur, and 
apoptosis will not be repressed, causing the cells to die.  
In addition to attachment, integrins are fundamental for all cell-matrix 
interactions including firm adherence and migration. Integrin activation is 
required for these interactions to occur, not simply surface expression. α5β1 
is important for firm adherence to fibronectin, but only in it’s activate state. 
The α5 integrin unit is also involved with migration to fibronectin, via 
Neuropilin 1 (NRP1). NRP1 binds to active α5 integrins, via the GAIP 
interacting protein C terminus (GAIP) mediating endocytosis for re-
presentation on the leading edge of migration (Simons, 2012). Fibronectin is 
upregulated after infarction therefore a similar mechanism could be involved 
in the migration and adhesion of stem cells to the ischemic myocardium (van 
Dijk et al., 2008). NRP1 is recognised as important for endothelial cell 
adhesion to fibronectin and therefore may have an important role for MSCs 
too (Valdembri et al., 2009). 
NRP-1 is a transmembrane glycoprotein that acts as a co-receptor for 
VEGFRs and SEMA3A that regulates vascular and neural development 
(Zachary, 2011). Mice with targeted NRP1 disruption have reduced blood 
vessel growth, particularly in the spine and brain (Fantin et al., 2013). Fantin 
et al, also showed identified the role of NRP1 in postnatal angiogenesis and 
arteriogenesis in the heart, with fewer coronary arteries and capillaries in the 
hearts of mice with mutated NRP1 compared to control hearts (Fantin et al., 
2014). NRP1 and VEGFR2 only interact in the presence of VEGF-A165 
activating signalling pathways involved in migration and angiogenic sprouting 
(Soker et al., 2002). However, NRP1 can function independent of VEGFR2 
supporting VEGF mediated endothelial cell migration through PI3K/Akt 
signaling in tumour cells not expressing VEGFR2 (Bachelder et al., 2001). 
Similarly MSCs express NRP1 but not VEGFR2. NRP1 in MSCs been shown 
to be an essential co-receptor with Platelet Derived Growth Factor Receptors 
(PDGFRs), particularly PDGFRα (Ball et al., 2010). This study identified the 
interaction between NRP1 and PDGFR as indispensable for migration of 
MSCs towards PDGF-AA & PDGFR-BB. 
 
4.3 Mechanism of action 
 
While the proposed mechanism of action behind benefits of transplanted 
BMSCs have yet to be fully deciphered, evidence is building that it is due to 
release of paracrine factors (Drexler and Wollert, 2009). The frequency of 
stem cell engraftement and transdifferentation detected is too low to have a 
significant impact. There is currently no evidence from human trials of 
transdifferentation to cardiomyocytes. Increasing microvasculature and 
neoangiogenesis, in addition to enhanced cardiomyocyte survival is often 
cited to be the basis of BMSC effects(Clifford et al., 2013). Also, transplanted 
cells found trapped in the lungs still proved to decrease infarct size by an 
immunomodulatory mechanism (Lee et al., 2009a). As such, release of 
cytokines and growth factors by transplanted BMSCs has been proposed as 
a major feature contributing to cardiac regeneration and repair (Figure 5).  
Approximately 40 of these secreted factors have the potential for cardiac 
repair, including VEGF, BMP2, IGF-1 and sFRP2 (Gnecchi et al., 2008a). 
Some researchers have suggested that delivery of an optimised variety of 
growth and cytokine factors could be all that is necessary post MI to exert the 
same benefit as administration of BMSCs. (Mirotsou et al., 2011). However, 
paracrine effects are not the only mechanism involved 
 
 
Figure 5 Proposed paracrine mechanisms for cardiac repair 
(Gnecchi et al., 2008b) 
In response to hypoxia BMSC release cytokines and growth 
factors induce signalling pathways leading to cardiac repair 
 
4.3.1 Neovascularisation 
Restoration of vascular supply to ischemic myocardium is vital as chronic 
ischemia after MI will cause negative ventricular remodelling that leads to 
heart failure. With the occlusion of the coronary artery, new vasculature can 
be formed by neovascularisation involving angiogenesis, arteriogenesis and 
vasculogenesis. The processes of angiogenesis and arteriogenesis involves 
growth factors including VEGF, bFGF and HGF. This leads to endothelial cell 
migration, vessel enlargement and extracellular matrix synthesis. BMSCs 
express these proangiogenic factors. A study injecting BM-MNCs into 
ischemic swine heart showed the cells not only expressed bFGF, VEGF and 
angiopoietin-1, but levels of interleukin 1β and TNFα in the myocardium were 
also increased after BM-mononuclear cell administration (Kamihata et al., 
2001). This resulted in an increased capillary density and localised blood flow 
to infarct region 3 weeks after initial coronary ligation. These secreted factors 
are likely to have contributed to stimulate angiogenesis. It has been reported 
that supernatant derived from cultured BMCs administered to MI mice has 
shown to have pro-angiogenic effects and protection against CMC necrosis 
and apoptosis (Korf-Klingebiel et al., 2008).  
 
4.3.2 Myocardial protection 
An important mechanism for reduction of infarct size is to improve 
cardiomyocyte survival after infarction. It is vital that this is an immediate 
effect in the ischemic region.  The Akt-1 pathway is important in the release 
of cytoprotective proteins (Gnecchi et al., 2005). Gnecchi et al  showed that 
by injecting cultured medium from Akt overexpressing cells into the infarct 
border, large reduction of cardiac apoptosis and infarct size was observed 
compared to medium from native MSCs. Subsequent studies idenitified 
VEGF, bFGF, HGH, IGF-1 and thymosin B4,  as upregulated in the Akt 
overexpressed MSCs after being exposed to hypoxia.  Native MSCs show 
the same upregulation of these proteins but to a lesser extent than the Akt-
MSCs. IGF-1 in particular prolongs the survival of the cardiomyocytes 
whereas another cytokine released by MSCs, Tumour Necrosis Factor α 
(TNF α), protects the CM against hypoxic damage (Meldrum, 1998).  
HGF has been associated with MSC migration, but there is also evidence 
that HGF imparts pro-survival effects on cardiomyocytes within the infarct 
zone (Gude et al., 2008),. HGF is the ligand for the receptor c-met that 
activates the PI3K/Akt pathway (Figure 6). This increases notch activation 
that leads to further akt phosphorylation. Gude et al have identified that 
activated overexpression of the notch pathway in infarcted hearts decreased 
the infarct size and increased anterior wall thickness, showing that not only 
does notch provide pro-survival effects but also stimulates CM proliferation. 
 Figure 6 Notch and HGF/c-met signalling pathways (Gude 
et al., 2008) 
 
 
4.3.3 Immunomodulation 
 
Not all BM cells administered are contained to the heart, they are often found 
in several other organs, mainly in the lung. Lee et al studied MSCs 
microembolised in the pulmonary vasculature. This caused major changes in 
the gene expression upregulating an anti-inflammatory protein TSG-6. TSG 
inhibits neutrophil migration into sites of inflammation and binds to 
hyaluronan fragments inhibiting their inflammatory effects.  
 
4.3.4 Cardiac remodelling 
Modulation of the post infarct scar can be altered by paracrine factors 
released from transplanted cells. Alteration of the extracellular matrix by 
decreasing collagen types I and III and tissue inhibitor of metalloproteinase 1 
reduces the infarct expansion. Injection to the border region of infarct 
myocardium has shown to decrease fibrosis and apoptosis while increasing 
myocardium thickness. Although there is no regeneration, cardiac function is 
preserved (Berry et al., 2006). 
 
4.3.5 Cardiac regeneration 
The ability to regenerate infarcted myocardium is the gold standard for 
cellular therapy.  However, there is very little evidence to suggest that 
transplanted BMSC are transdifferenting to cardiomyocytes in the infarcted 
border region. However, they may indirectly induce cardiac stem cells. 
Trophic growth factors HGF and IGF-1 have been shown have been shown 
to induce migration, proliferation and transdifferentation of cardiac stem cells. 
MSC release both of these proteins so may be recruiting CSCs when injected 
into the infarct area. Even at mRNA level HGF and IGF-1 was significantly 
upregualted in human BMSC treated hearts compared to controls (Yoon et 
al., 2005). The role on endogenous regeneration after BMSC treatment 
needs further investigation. While MSCs have showed promising results, 
hearts treated with HSCs, have not shown significant proliferation of CSCs or 
cardiomyocytes. In vitro work with EPCs has identified their ability to induce 
migration of c-kit+ cardiac progenitors (Urbich et al., 2005) 
It is probable that BMSC repair myocardium through several pathways 
involving myogenesis and angiogenesis. The model currently suggested 
involves the release of growth factors by transplanted stem cells that 
increase angiogenesis or aide in the survival of cardiomyocytes in the infarct 
region. Clinical trials have given modest results, but shown potential for 
development. There is great scope to improve this therapy by preconditioning 
the cells and selection of an individual cell population to create a more 
targeted cellular therapy to infarcted myocardium. 
 
 
 
 
 
 
 
 
Research question 
Can the adhesion and angiogenic functionalities of bone marrow derived 
stem cells be enhanced by preconditioning strategies in an in-vitro model? 
Hypothesis 
The adhesion and vascular support capacity of bone marrow derived stem 
cells can be enhanced by pharmacological preconditioning 
Aims and Objectives 
The bone marrow contains a very broad range of cells, and the aim of this 
project is to investigate if these bone marrow cells can be preconditioned to 
achieve a better therapy.  
1. To characterise the cells in the BM-MNC fraction, that are being used 
in clinical trials;  
2. Develop in-vitro assays to characterise their functional quality 
attributes associated with engraftment and angiogenesis capabilities, 
in conditions that mimic the environment of the ischemic heart 
3. To explore strategies to improve the retention & pro-vasculogenic 
potential of these bone marrow stem cells in an in-vitro model 
To do this I will be using bone marrow aspirates of patient samples from the 
REGENERATE-IHD clinical trial (NCT00747708) and healthy donor aspirates 
from University College Hospital.
Chapter 2 – Materials and methods 
 
The following methods are applicable to all chapters; all other methods and 
materials are further described in appropriate chapters. 
 
1. Cell culture 
 
All cell culture was carried out in laminar flow cabinets that had been pre-
cleaned with 70% ethanol. Aseptic technique was used to minimise risk of 
contamination 
 
1.1 Bone Marrow mononuclear cell isolation 
Bone marrow aspirates were obtained from healthy human donors, kindly 
donated by University College London Hospital. 1 part whole bone marrow 
(WBM) was diluted with 1 part Phosphate Buffered Saline (PBS). The 
mononuclear cell (MNC) fraction was obtained using a Ficoll density gradient.  
20ml of WBM was carefully pipetted onto 20ml of Ficoll-PAQUE PLUS (GE 
Healthcare;17-1440-02) in 50ml Falcon Centrifuge tubes. This was 
centrifuged at 650g for 30 minutes at 20°C with the brake/acceleration set to 
0. A band of MNCs is observed as an orange cloudy band above the clear 
ficoll and below dark red plasma. This MNC layer was removed with a 5ml 
pipette. The MNC fraction was washed with 3 parts dPBS to 1 part MNC and 
then centrifuged at 650g for 15 minutes at 20°C. The supernatant was 
discarded and cell pellets resuspended in 10ml of hMSC growth media (as 
described below). Cells were used in experiments or used to be seeded for 
mesenchymal stromal cell culture 
 
1.2 Media 
Human Mesenchymal Stromal Cells were maintained in Dulbecco’s modified 
Eagles medium (DMEM) low glucose (1g/L) plus GlutamaxTM (Invitrogen; 
10567-014), 1ng/ml recombinant basic Fibroblast growth factor (bFGF; R&D 
systems) and 10% v/v Fetal Bovine Serum (FBS; SLI, EU-000-F). Before use 
media was filtered using Millipore Express pore plus. Media composition was 
chosen from that of previous work on MSCs in the laboratory. 
Human Umbilical Cord Endothelial Cells (HUVECs) were maintained in EGM-
2 plus Bulletkit (Lonza; CC-3162). 
1.3 Mesenchymal Stromal Cell Culture 
After BM-MNC isolation (see §1.1) cells were counted using a 
haemocytometer and seeded at a density of 1 x 105 cells/cm2 in Nunc T75 
tissue culture flasks (Nunc, Stafford, UK) and maintained in a 5% CO2 
humidified incubator. Media was replaced after one day and then 
subsequently every 3 days. hMSCs were ready for passaging at 80% 
confluency.  
1.4 Cell Passaging 
Cells were passaged at ~80% confluency, unless stated. To passage all 
media was aspirated from tissue culture flask, and cells washed once with 
0.1ml dPBS/cm2. 0.25% Trypsin-EDTA (T/E; Invitrogen; 25200-056) was 
added in quantities as per Table 3. Flasks were incubated at 37°C for 3 
minutes and checked using a light microscope for cell detachment. The T/E 
was quenched with FBS containing growth media to neutralise the enzyme 
activity. Resultant cell suspension was transferred to a centrifuge tube and 
centrifuged at 300g for 3 minutes. Supernatant was then discarded and the 
cell pellet was resuspended in an appropriate volume of growth media. 
hMSCs and HUVECs were seeded at of 1 x 104 cells/cm2. Total volume for 
each culture vessel was made up to volume stated in Table 3 and media 
changed every 3 days. HUVECs were used up to passage 4. 
 
Flask size Media 
volume (ml) 
Trypsin 
Volume (mL) 
T75 12 2 
T25 5 1 
6 well 2.5 0.5 
12 well 1.5 0.3 
24 well  1 0.2 
48 well 0.5 0.1 
Table 3 - Appropriate volumes of trypsin and Media or specific cell 
culture dishes 
 
1.5 Cell Counting 
  
After centrifugation and resuspension cells could be counted using a 
haemocytometer. A haemocytometer glass slip was placed onto the 
haemocytometer with Newton’s rings formed between the slip and the 
haemocytometer slide. The cell suspension was pipetted up and down to 
ensure homogenous distribution and 10µl of the cell suspension was pipetted 
the top and bottom chambers under the glass slip. The total number of cells 
in the four corner square, each containing 16 smaller squares. For each 
chamber the total number of cells was averaged for each square (ie.4) and 
multiplied by 1x104. This gives the number of cells per ml since the volume of 
a square is 0.1mm3. This value and the volume of cell sample was used to 
calculate total number of cells in the cell sample.  
 
1.6 Storing Cells 
 
A working cell bank of MSCs was created from various isolations to serve as 
allow experiments to be repeated using the same isolation at different time 
points. To store cells they were first trypsinsed as described above. After 
centrifugation and aspiration of supernatant the cell pellet was resuspended 
in 10% Dimethyl sulfoxide (DMSO; Sigma; D5879) and 90% FBS. Cell 
concentration was adjusted to 1 x 106 cells/ml, and 1ml was added to each 
cryovial (Nuncleon). Cyrovials were then placed into a freezing container 
(Nalgene; 5100-0001) and then into a -80°C freezer to gradually reduce the 
temperature, by 1°C per minute, so the cells are not shocked, or stressed. 
The following day the cyrovials were placed into liquid nitrogen for long term 
storage. 
1.6 Thawing cells 
 
Required cells were removed from liquid nitrogen storage containers, and 
placed into a liquid nitrogen containing dewar until the thawing process. 
Cyrovials were thawed in a 37°C water for 2 minutes and gently resuspended 
before adding drop wise to 4ml pre-warmed growth media. This was 
centrifuged at 300g for 3 minutes and 21°C and cells were plated as per §1.3 
1.7 Mycoplasma testing 
 
To ensure all cultures were negative for mycoplasma, a small scrapping was 
made on the cell monolayer. 1ml of media was collected from the same flask 
and sent to Surrey Diagnostics (Cranleigh, UK) to analyse the samples for 
mycoplasma 
 
2. Immunocytochemistry 
Cells were fixed with 4% w/v paraformaldehyde (PFA) for 15 minutes. Fixed 
cells were then washed twice with dPBS. In order to eradicate non-specific 
interactions the cells were blocked using a blocking solution of 10% serum of 
species the secondary antibody is hosted from, and 0.25% v/v triton-X, for 40 
minutes at room temperature. The blocking solution was aspirated, and the 
primary antibody, at specified dilution was added to the well, and incubated 
overnight at 2-8C. This was then washed twice with dPBS and then 
secondary antibody at specified buffer was added and incubated for 1 hour, 
and before it was washed three times with PBS. A 1/10000 dilution of 4,6 
diamidino-2-phenylinode (DAPI) solution for 3 minutes and then washed 
once with dPBS and once with dH20. Fluorescence images were taken using 
a Nikon Eclipse TE2000-U fluorescence microscope, and analysed with NIS-
element software 
Primary and secondary antibodies: 
Host Antibody Reactivity Company Catalogue 
No 
Dilution 
Mouse 
IgG 
HCAM Millipore CBL154 1:500 
Mouse 
IgG 
THY-1 Millipore CBL415 1:500 
Mouse IgM STRO-1 Millipore MAB4315 1:500 
Mouse 
IgG 
MCAM Millipore MAB16985 1:500 
Mouse 
IgG 
CD14 Millipore MAB1219 1:500 
Mouse 
IgG 
CD19 Millipore MAB1794 1:500 
Mouse IgG1 PECAM R&D MAB2148 1:400 
Mouse IgG SMA R&D   
Goat IgG NRP1 R&D AF566 1:100 
Chicken IgG Alexa 
Flur 488 
Goat IgG Invitrogen A-21467 1:200 
Goat IgG Alexa 
Flur 488 
Rat IgG Invitrogen A-11006 1:1000 
Goat IgG Alexa 
Flur 555 
Mouse IgG Invitrogen A-11001 1:1000 
Goat IgG Alexa 
Flur 488 
Mouse IgM Invitrogen A-21042 1:1000 
Goat IgG Alexa 
Flur 488 
Rabbit IgG Invitrogen A-22008 1:1000 
Goat IgG Alexa 
Flur 555 
Rabbit IgG Invitrogen A-21428 1:1000 
 
Before each antibody was used to ensure accurate interpretation of results, 
negative, and where possible, positive controls were used.  
No primary antibody control – To test any possible background emittance 
from the secondary antibody alone 
Isotype Control – Samples were incubated with the Mouse IgG negative 
control (CBL10, Millipore, UK), using the same method as described above, 
and then incubated with the desired secondary antibody, before being viewed 
using the fluorescence microscope. This ensured background staining was 
negligible.  
3. Characterisation of MSCs 
 
MSCs were confirmed according to the current ISCT definition ie. Their 
adherence to tissue culture plastic; specific surface antigen expression  of 
CD105+, CD90+, CD73+, CD19-, CD14- and trilineage differentiation 
potential to osteoblasts, adipocytes and chondroblasts. These assays were 
carried out as described  
3.1 Trilineage Differentiation 
3.1.1 Osteogenic differentiation 
MSCs at stated passage and experimental group were seeded into a 12 well 
plate for classical stain differentiation, and a T25 for a gene expression study, 
both at a seeding density of 5 x103 cells/cm2 with normal MSC growth media. 
After 2 hours incubation at 37C media was replaced by Complete 
Osteogenic Differentiation Media (Invitrogen, UK). Gene expression studies 
were harvested after 24 hours. Otherwise, cultures were refed every 4 days. 
After 21 days media was removed and cells were fixed with 4% 
paraformaldehyde solution for 15 minutes. After fixation the wells were rinsed 
with distilled water and stained with 2% Alizarin Red S solution (pH 4.2; 
Sigma) for 3 minutes. Wells were rinsed 3 times with distilled water and 
visualised under a light microscope  
 
3.1.2 Adipogenic differentiation 
MSCs at stated passage and experimental group were seeded into a 12 well 
plate for classical stain differentiation, and a T25 for a gene expression study, 
both at a seeding density of 1 x104 cells/cm2 with normal MSC growth media. 
After 2 hours incubation at 37C media was replaced by Complete 
Adipogenic Differentiation Media (Invitrogen, UK). Gene expression studies 
were harvested after 24 hours. Otherwise, cultures were refed every 4 days. 
After 14 days media was removed and cells were fixed with 4% 
paraformaldehyde solution for 15 minutes. After fixation the wells were rinsed 
with distilled water and stained with 4% Oil Red O solution (Sigma) for 5 
minutes. Wells were rinsed 3 times with distilled water and visualised under a 
light microscope  
 
3.1.3 Chondrogenic differentiation 
MSCs at stated passage and experimental group were harvested and 
generated to a cell concentration of 1.6 x 107 cells/ml. A micromass culture 
was generated by seeding 5ul droplets of cell solution into the centre of a 6 
well plate well. After incubating micromass for 1 hour 2ml warmed 
chondrogenesis media (Invitrogen,UK) is added. Media was replaced every 3 
days. After 14 days media was removed and cells were fixed with 4% 
paraformaldehyde solution for 15 minutes. After fixation the wells were rinsed 
with distilled water and stained with 1% Alician blue (Sigma, UK) prepared in 
0.1N HCl for 30 minutes. Wells were rinsed 3 times with 0.1 HCL then 
distilled water to neutralise the acidity, and observed under the light 
microscope. 
 
3.2 Surface marker expression 
MSCs, at stated passage, were grown to 80% confluence and prepared for 
immunocytochemsitry as according to section 2. Fixed cells were probed for 
CD44, CD90, CD105, CD14 and CD19  
 
4. Quantitative Polymerase Chain Reaction 
 
Gene expression was quantified using qualitative polymerase chain reaction 
(qPCR). RNA was isolated from harvested cells using Qiagen RNeasy kit 
(Qiagen, UK). In brief cells pellets were resuspended using RLT buffer and 
centrifuged in a QIAshredder at full speed for 1 minute to homogenise the 
cell suspension. Then RNA was isolated according to the manufacturer’s 
instructions. RNA was eluted from the column using 14l of RNase-free 
water and quantified using a Nanodrop. cDNA was then synthesised using 
Reverse Transcription kit following manufacturer’s instructions. For each 
reaction a master mix was made up of 1µl Quantiscript reverse transcriptase, 
4 µl RT buffer, and 1 µl of RT primer mix, which was added to 14ul of 
template RNA. In a thermocycler this was incubated at 42ºC for 15 minutes, 
followed by 3 minutes at 95ºC 
Resulting cDNA was used with SYBR green Quantitect (Qiagen, UK) and 
Quantitect Primers. This was detected using CFX Connect Real time PCR 
Detection system (Bio-Rad, UK). The cycling conditions for the two step RT-
PCR were as follows: 
PCR initial activation step – 15 minutes at 95°C 
3 Step cycling, repeated for 40 cycles : 
1. Denaturation – 15 secs at 94°C 
2. Annealing – 30 secs at 55°C 
3. Extension – 72 secs at 72°C 
Cq values obtained for each gene were normalised to the housekeeper gene, 
GAPDH. 
5. In-vitro functional assays 
Throughout the thesis the same optimised in vitro assays are used to access 
static adhesion, migration and angiogenic potential, except where specified. 
5.1 Static adhesion 
 
Cell adhesion assays were performed in 48-well plates that were coated with 
20 ng/ml fibronectin (R&D Systems). Wells were then washed three times 
with PBS and blocked with 2% BSA in PBS for 1 h at 37°C. Then, 2% Bovine 
Serum Albumin (BSA; Sigma Aldrich) in PBS alone-coated wells was used as 
negative control. 1 x 104 MSCs, at passage 3 or 5, or BM-MNCs per well 
were seeded on fibronectin-coated plates and cells were incubated in hMSC 
media for 5, 20 and 40 mins at 37°C. Non-adhered cells were aspirated and 
wells were washed twice with PBS. Cells were photographed using a Nikon 
Eclipse TE2000-U microscope for assessment of adhesion at x 4 
magnification in 3 random fields of view. 
 
5.2 Chemotaxis 
Chemotaxis of hMSCs and BM-MNCs were performed in 24 well plates (BD; 
353503) with 8-µm pore cell culture insert (BD; 353182). Serum free media 
was added to the lower well and insert and incubate for 1 hour to allow 
equilibrium. The cells were suspended in serum-free DMEM + Glutamax at a 
concentration of 3 x 105/ml. Then, 1 x105 cells in 400 µl/well were loaded onto 
the upper chambers. The lower chambers were filled with serum-free DMEM 
+ Glutamax containing 0 or 100 ng/ml SDF-1. After 3 hours incubation at 
37ºC, the non-migrating cells were aspirated and then gently scraped from 
the upper membrane using cotton swabs. The membranes were fixed in 2% 
paraformaldehyde for 10 minutes and washed twice in PBS. The migrated 
cells were stained with 0.5% crystal violet (Sigma, UK) in 5% ethanol for 30 
mins. The membrane was mounted on a microscope slide and migrated cells 
counted in three random fields of view at x 10 magnification. Cell counting 
was performed using ImageJ, all counts were nromalised to the mean of the 
control ie. Number of cells on membrane with serum free media in lower well. 
This is known as the migration index. 
For migration of MNCs, as the cells are non-adherent, the cells do not attach 
to the membrane and locate to the bottom of chamber where they are fixed, 
stained and identified as above.  
 5.3 Tubule formation 
The ability of MSCs to form tubule like structures was assessed using an in 
vitro angiogenesis assay(Salani et al., 2000). 50μl Matrigel Growth Factor 
Reduced (BD; Cat.no. 354220) was added to wells of a precooled 96 well 
plate and incubated at 37°c for 1 hour.  1 x 104 hMSCs, or BM-MNCs, in 
150µl EGM-2 media per well were seeded onto the Matrigel.  
Cells were then incubated for 18 hours and vessel branch formation was 
counted using ImageJ software. The structures were then fixed in 4% 
Paraformaldehyde (PFA) for 10 mins and washed 3 times in PBS, then 
blocked with 10% Goat Serum (Invitrogen,UK) for 30 minutes. Cells were 
then immunolabelled with 1/1000 diluted, mouse anti-PECAM1 (Millipore, 
UK) and 1/200 mouse anti-αSMA (R&D Systems, UK) overnight at 4°C. 
These were treated with 1/1000 Alexa Flour 488 Goat Anti-mouse antibody 
for 1 hour, followed by 3 minutes treatment of 1/1000 DAPI for nuclei 
staining. 
Human Umblical Cord Vein Endothelial Cells (HUVECs) were used as a 
positive control. 
5.4 Vascular support assay 
To assess the ability of MSCs to support a pre-existing network of endothelial 
cells they were seeded onto a pre-formed network of HUVECs and observed 
over the next 24 hours. 
 
5.5 Hypoxia 
To mimic the ischemic environment after infarct all experiments were 
repeated in a hypoxic environment. Plates were placed inside a custom 
made humidified hypoxic chamber purged at 2% oxygen to mimic an 
ischemic environment. Manufacture and validation of the chamber, as 
previously described (Mondragon-Teran et al., 2009) 
 
6. Statistical analysis 
 
All experiments were performed in triplicate with at least 3 different isolations 
of MSCs or MNCs. Data is expressed as mean ± SEM. Differences were 
analysed by Analysis of Variance (ANOVA). A P-value less than 0.05 was 
considered statistically significant. Microsoft Excel and SPSS software were 
used to perform the statistical analysis 
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Chapter 3 – Engraftment response of Bone marrow stem 
cells to preconditioning with SDF-1 
 
Introduction 
 
Traditional priming strategies for stem cells are concentrated on 
increasing the survival of transplanted cells, but this is unlikely to 
increase efficacy post injection due to intrinsic MSC biodistribution. This 
may be enhanced by optimising adhesion and migration to target the 
intended region of interest ie. Infarct myocardium. The advantage of this 
is that it avoids complex delivery to such tissues and will reduce the 
number of cells required for therapeutic application.  Stimulation with 
stromal derived factor 1 (SDF1) is one such strategy that will be 
investigated in this chapter. 
SDF1 is a chemokine of the CXC family that interacts specifically with 
CXCR4 and CXCR7, G-protein coupled receptors (Nagasawa et al., 
1994). SDF1 and CXCR4 are expressed in many cell types and tissues. 
SDF-1 is over expressed on myocardial infarction, however this is only 
short term and decreases after 7 days (Askari et al., 2003). SDF-1 
mediates a response via CXC4R increasing the expression of VEGF-A 
and further. In endothelial cells stimulation with SDF-1 has been reported 
to up regulate α1, 4 and 5 integrins and increased adhesion (De Falco et 
al., 2004). Integrin α5β1 is involved in firm adhesion to fibronectin, an 
extracellular matrix protein that is expressed in the ECM after myocardial 
infarction, therefore stimulation with SDF-1 would suggest improved 
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engraftment within a post infarction environment (Zhang et al., 2008). 
Integrin β1 (CD29) is important for not only adhesion, but also migration 
and blockade has shown to significantly decreased percentage of cells 
adhered (Ip et al., 2007). Adhesion isn’t the only functionality of the cell 
that is modulated, SDF-1/CXCR4 signalling also activates PI3K/Akt 
pathway that contributes towards cell survival, proliferation and migration 
(Kucia et al., 2004). Pasha et al demonstrated in-vitro and in-vivo models 
for use of MSCs by stimulation with SDF-1 in a rat infarct model. They 
concluded this was primarily due to the activation of this Akt pathway by 
SDF-1. 
In the current study, we assessed the effect of SDF1 pre-conditioning on 
hMSCs and BMCs in vitro to determine whether functional cell 
characteristics, attachment and migration, both of which are required for 
cell retention, are improved. Experiments were performed using hMSCs 
at passage 3, reflective of the typical in vitro passage number at which an 
hMSC product might be obtained; and passage 5, to reflect the limit of 
acceptability of hMSC products based on literature reports of proliferation 
rate, clonogenicity and differentiation potential (Bertolo et al.; Madeira et 
al., 2012 
). Subsequently, we performed experiments using passage 3 hMSCs in 
hypoxia (2% oxygen) to determine functional characteristics in conditions 
that more closely mimic the physiological oxygen tensions 
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Hypothesis 
Stimulation of human bone marrow derived MNCs and MSCs with SDF-
1 will increase their adhesion, migration and angiogenic potential. 
 
Method & Materials 
All methods and assays are as described in Chapter 2, except the 
assays were not performed in hypoxic conditions for MNCs due to the 
limited of cell samples obtained from the REGENERATE trial (Table 1). 
Table 4 – Patient medical details of Bone Marrow Mononuclear cells 
used 
Patient 
ID 
Trial Hypertension Hypercholesterolemia Smoking 
status 
NYHA 
class 
X31 DCM No No Non II 
X107 IHD No No Ex II 
X131 IHD Yes Yes Ex II 
X03 IHD Yes Yes Ex III 
X105 IHD Yes No  Ex III 
X116 IHD No Yes Non II 
 
To precondition cells, a final concentration of 100ng/ml SDF-1 (R&D 
Systems) was added to the tissue culture flask for either 1 hour (acute) or 
overnight (chronic). The bone marrow monouclear cells were in 
suspension, so therefore could only be preconditioned in an acute 
setting, otherwise their viability would have been compromised. 
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MNCs were obtained following written, informed consent and approval 
from the Local Research Ethics Committee in accordance with the 
Declaration of Helsinki, from patients recruited to the REGENERATE 
phase II clinical trial (NCT00747708). The REC responsible was South 
West REC and the reference number for the project is: 04/Q0603/13. 
 
Results 
Characterisation of bone marrow derived mononuclear cells 
Isolated cells in the lymphocyte/monocyte region of the ficoll separation 
were characterised for their surface marker expression of CD34/CD45, 
CD133 and VEGFR2 (Figure 7B). The fractions of lymphocytes was also 
accounted for by CD45 positive cells with appropriate side scatter, with 
CD3 positive for T cells, CD19 positive for B cells, and CD15/56 positive 
for Natural Killer cells (Figure C).  
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Figure 7 Flow cytometry analysis of mononuclear cell isolations. 
(A) Flow cytometry dot plot, of CD133 (APC) and VEGFR2 (PE). Highly 
expressing CD133+/VEGFR2+ cells appear in yellow, in box P2. (B) 
Population percentage of HSC and Endothelial progenitor cells according 
to surface markers CD35/45 and CD133/VEGFR2. (C) Lymphocyte 
constituents of mononuclear cell isolation 
Isolation of Bone Marrow derived Mesenchymal Stem cells 
Lymphocyte and monocytes cells, containing the stem cell population, 
were isolated by ficoll density centrifugation. Cells of mesenchymal 
morphology appeared after 4 days, and became confluent after 14 days 
(Figure 8). Mesenchymal cells appear at Day 4 (D4). D5-7 mesenchymal 
colonies can be seen. By D14 plate is confluent, containing 
mesenchymal stem cells and other unidentified adherent populations 
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Figure 8 Chronological observation of mesenchymal stem cell growth 
from bone marrow isolation. Mesenchymal cells appear at Day 4 (D4). 
D5-7 mesenchymal colonies can be seen. By D14 plate is confluent, 
containing mesenchymal stem cells and other unidentified adherent 
populations 
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Figure 9 - Heterogeneous adherent cell population in the bone marrow 
After density centrifugation of bone marrow sample lymphocyte and 
monocyte cells were cultured on plastic and after 12 days with regular 
changes the primary culture contained mesenchymal stem cells 
(according to morphology) and unidentified round cells, showing the bone 
marrow contains other adherent population of cells than MSCs. In figure 
A the round cells (BLUE region) are cluster on the tissue culture flask 
surround by MSC (RED region). Figure B shows a different area of same 
tissue culture flask that is less confluent containing cells of different 
morphology (red and blue arrows).  
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Characterisation of Mesenchymal stromal cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Characterisation of bone marrow derived MSCs. MSCs at 
passage 3 and 5 were characterised under the definition of the 
International Society of Cellular therapy. Cells are adherent to plastic and 
show a spindle like morphology (A-B). Black arrows represent cells that 
have become hypotrophic in passage 5. They were positive for HCAM, 
STRO-1/THY1 and negative for CD14 and CD19 (C). All MSCs displayed 
their plasticity to differentiate to adiopgenic, chondrogenic and 
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osteogenic lineages. MSCs were stained with oil red O, alcian blue and 
alizarin red respectively (D). Scale bars represent 100µm 
 
MSCs were grown in DMEM with 10% FBS and 1ng/ml bFGF and 
cultured to 5 passages, and characterised at passage 3 and 5 in 
accordance to the ISCT guidelines.  MSCs at passage 3 and 5 showed 
comparable morphology (Figure 10A-B), of a long and thin striated 
appearance with a large nucleus (Figure 10B). However in passage 5 
some cells within the culture became enlarged and hypertrophic. 
Subsequent passages were observed to contain many cells with this 
morphology (data not shown). MSCs at both passage 3 and 5 expressed 
CD44, STR0-1 and THY-1 but not lymphocyte and T-cell markers CD14 
and CD19 (Figure 10C). Both passages were capable of tri-lineage 
differentiation confirming identification as Mesenchymal Stromal Cells 
(Figure 10D). 
Adhesion of MSCs enhanced by fibronectin not SDF 
To determine the functional MSC attachment to ischemic myocardium I 
studied the effect of in vitro of SDF-1 preconditioning in time dependant 
adhesion to fibronectin, an extracellular matrix component upregulated 
after myocardial infarction. After expansion, MSCs were grown to 80% 
confluency, harvested and resuspended in serum free media. 
1x104MSCs were seeded onto BSA or Fibronectin (FN) coated wells in a 
96 well plate. Significantly more cells adhered to fibronectin compared to 
wells coated with BSA, within 40 minutes for both passages (Figure 11B). 
Significantly more cells adhered to fibronectin over 20 minutes and this 
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was consistent in 2 different isolations. For MSCs in passage 3, neither 
acute nor overnight preconditioning with SDF-1 increased amount of cells 
adhere (Figure 12B). However, in passage 5, there was significantly 
more cells adherent than control cells on fibronectin (p<0.05) within 5 
minutes (Figure12B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Adhesion of MSCs. Passage 3 (p3) and 5 (p3) MSCs were 
grown in normal media to confluency and harvested. After resuspension, 
1x104 MSCs were seeded to BSA and fibronectin for 5,20 and 40 
minutes, fixed and stained for DAPI for counting on ImageJ software (A). 
MSCs adhere preferentially to fibronectin than non-specific protein in 3 
different MSC isolations (B-E). *=p<0.05 between p3 and p5 
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Figure 12 – Effect of SDF-1 conditioning for MSC adhesion. MSCs were 
stimulated with SDF-1 either for 1 hour (acute pc) or overnight (o/n pc). 
SDF-1 had increased adhesion of passage 5 cells over minutes (A) and 
in isolations from Donors B and C (C-D). *=p<0.05 versus control in time 
course 
Adhesion of BM-MNC increased by fibronectin, not SDF-1 
preconditioning. Bone marrow mononuclear cells adhered significantly 
greater to Fibronectin than a non-extracellular matrix regardless of SDF-1 
stimulation (Figure 13A-D). This is consistent for each patient sample 
that was used, however BM-MNCs from patient 31 (Figure 13D) had 
greater amount of cells adhered after 20 minutes for all experiment 
groups than cells from patient 131 (Figure 13B) and patient 107 (Figure 
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13C). This variability dependant on patient isolation is represented in the 
cumulative data (Figure 13A)  
 
 
 
 
 
 
 
 
Figure 13 SDF-1 does not increase adhesion of BM-MNCs. BM-MNCs 
were obtained from individual patient samples from the REGENERATE –
IHD and DCM clinical trial (A-C). BM-MNCs were preincubated in hMSC 
media in the absence or presence of SDF-1 (100ng/ml) for 30 mins (PC) 
and overnight and were allowed to adhere to the wells FN and BSA 
coated wells for 5, 20 and 40 mins (A). Adhesions were quantified by 
microscopy. Adhesion data represent the mean ±SD of triplicate samples 
from 3 independent experiments (B-D). BSA – Bovine Serum Album 
coated wells; PC- preconditioned cells (100ng/ml SDF-1) FN- Fibronectin 
coated wells. *= P<0.05 between BSA control vs. FN groups 
3.3.1 MSCs migrate towards an SDF-1 gradient 
SDF-1 is over expressed by the ischemic myocardium for 7 days (Penn, 
2009), the chemotaxis of MSCs to SDF-1 was determined in a transwell 
 84 
migration assay. I investigated whether preconditioning cells with SDF-1 
would enhance the migration response. MSCs were grown in normal 
growth media and harvested at 80% confluency for use in the chemotaxis 
experiments 
Both unstimulated and stimulated groups showed significant migration 
towards SDF-1 compared to control. Interestingly, while preconditioning 
of passage 3 MSCs with SDF-1 did not affect migratory response, 
passage 5 cells preconditioned with SDF-1 had a significant increase in 
cells (p<0.05). In addition passage 5 cells have diminished chemotaxis to 
SDF-1(Figure 14B). Migration was also variable between individual MSC 
isolations  
 
A 
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Figure 14 MSCs preferentially migrate towards SDF-1. The effects of 
MSC migration were determined by exposing MSCs to 100ng/ml SDF-1 
in the lower chamber of the transwell for 3 hours. The transwell 
membrane was not coated. Cells were placed in the transwell upper 
chamber with serum free media. After 3 hours of incubation non-
migrating cells were scraped off with cotton swabs.  Migrated cells on the 
membrane were stained with crystal violet, images taken at x10 
magnification (A).  The migrated cells were quantified by observing three 
random microscopic fields for each membrane (B). Control – MSCs in 
serum free media and serum free media in lower well. Both unstimulated 
and stimulated groups have SDF-1 (100ng/ml) in lower well. This was 
repeated using 3 different MSC isolations (C-E) * = p<0.05 
BM-MNC chemotactic response to SDF-1 is population specific 
The chemotactic response of BM-MNC to SDF-1 was investigated in a 
transwell migration assay. 3 patient BM-MNC samples were used and 
chemotactic response to SDF-1 was varied (Figure 15). Isolate 31 
showed a 10-fold increase compared to the control, while x131 displayed 
no increase when compared to control.  
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Figure 15 - Chemotaxis of BM-MNCs to SDF-1. Cells were seeded into a 
transwell with 8um pores with and without SDF-1 in the lower well as the 
chemoattractant .x31, x107, x131 represent individual patient samples of 
BMMNCs. *=p<0.05 versus control 
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SDF-1 stimulation of MNCs stimulates EPC phenotype  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Flow cytometry analysis of patient derived MNCs. A population 
of MNCs highly expressing CD133 and VEGFR2 (KDR) was gated (A). 
MNCs were stimulated with control or SDF-1 (100ng/ml) for 30 minutes. 
Then cells were analysed by flow cytometry for CD133/KDR expression 
(B). This was repeated with 3 different patient isolations (C-E) 
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SDF-1 does not increase in vitro tubule like structures formation of 
MSCs 
 
To investigate the network forming capacity, MSCS were seeded onto 
matrigel in EGM-2. EGM-2 contains several growth factor and 
supplements that include epidermal growth factor, insulin like growth 
factor 1, VEGF, ascorbic acid, hydrocortisone, bFGF when seeded onto 
matrigel with EGM-2 media have a distinctive phenotype change to form 
tubule like structures (Figure 17A), however no structures were formed 
when seeded with normal culture media., These structures were 
quantified for branch point formation (Figure 17B) and no difference was 
found in those cells preconditioned with SDF-1. HUVECs formed more 
uniform vessel structures and had 1.6 fold more branch formations. 
MSCs are alpha smooth muscle actin (αSMA) expressing and 
Platelet/endothelial cell adhesion molecule 1 (PECAM-1) negative, while 
HUVECs are PECAM-1 expressing, and weakly expressing αSMA 
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Figure 17 - SDF-1 does not increase tubule like structures. Cells 
were fixed and expression of PECAM-1 and aSMA and DAPI (for nuclei 
staining) detected by immunocytochemistry in matrigel (A) and tissue 
culture plastic (B). Images taken at x10 magnification. MSCs were added 
to 96 well plates coated with matrigel with and without SDF-1. HUVECs 
were used as a positive control. Plates were incubated for 18hours to 
allow tubule like structure formation (C) Individual vessel formations were 
quantified (D-G) * = p<0.01 vs control. Scale bars represent 100um 
F      G 
 
*
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BM-MNCs do not form tubule like structures in Matrigel 
BM-MNCs from patient samples were seeded onto matrigel and after 18 
hours, unlike the MSCs, did not form tubule like structures, and clustered 
in the centre of the well (Figure 18A). This was not affected by SDF-1 
preconditioning (Figure 18B) 
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Figure 18 - MNCs do not form tubule like structures in matrigel. MNCs 
did not form any tubular network (H) regardless of preconditioning (I). 
Scale bars represent 100um 
 
A 
B 
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Hypoxia abrogates cell adhesion 
 
In order to replicate the ischemic environment, the assays were repeated 
in a hypoxic chamber purged with 2% oxygen. Significantly less cells 
adhered to fibronectin within 5 and 20 minutes in the hypoxic 
environment compared to normoxia (Figure 19). This trend was repeated 
with the patient MNCs and consistent in all isolations (Figure 20). 
However, no effect was observed in migration or tubule formation of the 
MSCs in hypoxia compared to normoxia (Figure 21). However, donor A 
showed significant decrease in migration, and increase in number of 
vessel branches formed in hypoxia compared to normoxia. Hypoxia did 
significantly increase vessel formation in one isolation, but no affect in 
the other 2 (Figure 22B). 
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Figure 19 Effect of hypoxia on MSC attachment. The effect of hypoxia 
was assessed in passage 3 MSCs for 5 minutes (A-D) and 20 minutes 
(E-H). Hypoxia impaired rate of attachment to FN. Preconditioning with 
SDF1 did not affect attachment. Data represents mean ± SEM for (A, E) 
and mean ± SD for each independent experiment (B-D, F-H). * = p<0.05 
Normoxia vs hypoxia. 
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Figure 20 Effect of hypoxia on MNC attachment. The effect of hypoxia was assessed 
in passage 3 MSCs for 5 minutes and 20 minutes. Hypoxia impaired rate of 
attachment to FN. Preconditioning with SDF1 did not affect attachment. Data 
represents mean ± SEM for (A) and mean ± SD for each independent experiment (B-
D). * = p<0.05 Normoxia vs hypoxia. 
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Figure 21 Effect of hypoxia on MSC chemotaxis. Chemotaxis of passage 
3 MSCs overall appeared not affected by hypoxia when combined data 
was assessed (A). However, when considering individual donor samples 
(B-D), evidence of impaired migration was seen in MSCs from one of the 
three independent donor samples (B). Data represents mean ± SEM for 
(A) and mean ± SD for each independent experiment (B-D). * = p<0.05 
Normoxia vs hypoxia. 
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Figure 22 - Effect of hypoxia on MSC tubule formation. Hypoxia had 
some significant increase in tubule formation on the control MSC group 
(A), but not for preconditioned groups. Data represents mean ± SEM for 
(A) and mean ± SD for each independent experiment (B-D). * = p<0.05 
Normoxia vs hypoxia. 
 
 
 
 98 
Discussion 
SDF-1 is a chemokine that is implicated in migration of BM-MSC and 
Haematopoietic stem cells (HSCs). The chemokine is over expressed in 
the ischemic myocardium for 7 days post infarct (Ghadge et al., 2008). 
SDF-1 is a chemoattractant to cells expressing its receptor CXCR4 
(Kucia et al., 2004). Preclinical studies in rat myocardial infarction (MI) 
model have shown that preconditioning of MSCs with SDF-1 can improve 
their survival, can increase vasculature in the ischemic myocardium, and 
decreased infarct size (Pasha et al., 2008). However, the effect to 
engraftment and chemotaxis was not studied. In addition, these findings 
may be as a consequence of the increased cell survival. Therefore this 
study aimed to show the in-vitro role of SDF-1 preconditioning in MSCs 
and BM-MNC for adherence, migration and vessel formation.  
The major findings of this study found that: i) the extracellular matrix 
component, Fibronectin, was more important for to adhesion than SDF-1 
preconditioning; ii) MSCs can form similar tubule like structure in a matrix 
to HUVECs, but is not enhanced by preconditioning; iii) BM-MNCs do not 
form tubule like structures; iv) MSCs and BM-MNCs migrate towards a 
SDF-1 gradient; v) Migration response of MSCs is dependent on their 
maturity, and the response of passage 5 cells is enhanced by SDF-1 
preconditioning.  
Post-MI several extracellular matrix components are upregulated, 
including fibronectin (Knowlton et al., 1992). SDF-1 has been to shown to 
upregualte 51 in another cell type present in the bone marrow, 
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endothelial progenitor cells (Ghadge et al.). This integrin is vital for firm 
adhesion to fibronectin therefore upregulation would enhance amount of 
cells adhered. The majority of animal studies that have shown a greater 
number resided within the myocardium results in increased cardiac 
function 
Passage 5 MSCs stimulated overnight with SDF-1 adhered to fibronectin 
significantly greater in 5 minutes compared to unstimulated MSCs. This 
was abrogated after 20 minutes where there is no difference. There is no 
difference between adhesion at 20 and 40 minutes for all experimental 
groups, so most adhesion occurs within 20 minutes. Rapid firm adhesion 
is vital within the ischemic myocardium as many cells are lost to other 
parts of the body. Suzuki et al showed that that 44% of transplanted cells 
survived for 10 minutes and decreased to 15% within 24 hours (Ohtsuka 
et al., 2004). Using a hypoxic culture chamber, we characterized rapid 
attachment of hMSCs up to 20 minutes and found an enormous 
significant reduction in hypoxic conditions. Hypoxia has also been 
reported to reduce attachment of endothelial cells (Kaiser et al., 2012) 
However, it is of particular significance for transplantation of hMSCs into 
ischemically injured tissues. Furthermore, preconditioning cells with 
SDF1 was not able to prime cells to rescue this phenotype. 
The ischemic myocardium releases SDF-1 into the microenvironment 
and recruits bone marrow mesenchymal cells (Abbott et al., 2004; 
Zhuang et al., 2009). This study shows MSCs preferentially migrate 
towards SDF-1. Chemotaxis occurs via the SDF-1/CXCR4 axis so 
changes to the CXCR4 expression will affect migration (Cheng et al., 
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2008; Ip et al., 2007). After multiple passaging of MSC ex-vivo culture 
CXCR4 expression is markedly reduced (Fiedler et al., 2004; Wynn et al., 
2004). Passage 3 and 5 are significantly different in their migratory 
response due to reduced CXCR4 expression. The importance of CXCR4 
expression is reinforced by a study that identifies MSCs exogenously 
over expressing CXCR4 expression have a three fold increase in 
migration to SDF-1 than non transfected MSCs (Cheng et al., 2008).  
MSCs at passage 5 have diminished chemotactic response that is 
increased with preconditioning with SDF-1. SDF-1 has been shown to 
induce an autocrine loop whereby CXCR4 is upregulated (Ghadge et al., 
2008), thereby enhancing chemotaxis. However, this enhancement does 
not increase it that of the lower passage. This is important for therapy, as 
homing towards the infarcted myocardium may be reduced by low 
CXCR4 expression, therefore use of MSCs at a lower passage would be 
recommended. 
There was no trend between patient derived BM-MNC chemotaxis to 
SDF-1. The response varied from a 10 fold increase to no change when 
compared to control. Therefore, this individualised response would 
dramatically impact the effect these cells would have when transplanted 
into the ischemic microenvironment. Isolated Bone marrow mononuclear 
cells contain a heterogeneous population of cells and have been the 
subject of clinical trials in cardiac repair for the past decade. This 
variability between samples could induce variable end outcomes. No 
statistical conclusions can be made between the assay outcomes and 
the medical history of the patients from which the cells were obtained. 
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However, cells from ex smokers (X107 and X131) adhered and migrated 
less than those from a non smoker (X31). MNCs contain a small 
population of EPCs. Another study have been shown EPCs to become 
dysfunctional and senescent in smokers, the same phenomenon could 
be occurring in the less responsive patient cells, although this is purely 
speculative (Michaud et al., 2006).  
While the mechanism of action is still unclear for MSC therapy, animal 
models have previously shown preconditioning with SDF-1 enhances 
capillary density within the ischemic myocardium (Pasha et al., 2008). I 
mimicked in an in vitro 3D matrix assay that shows tubule formation, but 
SDF-1 does not enhance total branch formation. However, the limitations 
of the in vitro model do not account for any increased cell survival, 
engraftment or migration that may occur in vivo model. Also, the 
morphological features of the tubules bear little resemblance to 
capillaries formed in vivo. In addition the assays are carried out in EGM-2 
that includes Vascular Endothelial Growth Factor and Insulin Growth 
Factor known angiogenesis stimulants. Their potency could mask any 
potential effect SDF-1 may have. In addition, BM-MNCs show no 
morphological changes in this assay. The heterogenous population of 
MNCs was not expected for these cells to form tubules on their own 
within matrigel due to a high proportion of haematopoeitc stem cells and 
macrophages that do not form this phenotype. However, their interaction 
with an existing vasculature is unknown. 
It is notable that different isolations had variable results within the assays 
and response to SDF-1. If MSCs were to be used for therapy, using 
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different donors could therefore have differing outcomes. For instance 
those MSCs that show increased engraftment to fibronectin would be a 
lot more suitable. These assays could be utilised to identify suitable cell 
lines. Few studies have highlighted the disparity between isolations. Lo 
Surdo and Bauer showed differences of differentiation capacity and 
clonogenicity, albeit only comparing 2 different donor isolations (Lo Surdo 
and Bauer, 2012). 
A possible source of variability is the FBS used in the normal growth 
media. FBS is produced by extraction of clotted whole blood collected 
from the fetus by cardiac puncture (Wappler et al., 2013). Therefore in 
each extraction there is lot to lot variability, as each batch contains 
differing amounts of proteins and other growth factors. Using different 
batches of FBS could have resulted in different growth characteristics 
and function of the MSCs. 
The key findings from this study are that: i) By passage 5 using a 
standard cell expansion procedure, the attachment and chemotactic 
migration profiles of hMSCs was significantly altered and therefore the 
degree of subculture can impact on critical cell functions even where 
potency is seemingly conserved; ii) SDF-1 preconditioning did not 
substantially improve these responses other than a mild initial (5 minute) 
improvement in attachment indicating that sustained effects of SDF1 
reported in some animal studies is independent of attachment and 
migration capacity of MSCs; iii) Hypoxia significantly impairs the rapid 
attachment of hMSCs to fibronectin but that migration is not significantly 
affected according to cross donor analysis; iv) Inter-patient variability is 
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substantial and therefore can make measurement of essential functional 
responses (and consequently development of assays to measure 
function and potency of the cell product) difficult. 
 
Conclusion 
This study shows there is no evident effect of the engraftment by 
preconditioning bone marrow derived cells with SDF-1 either in an acute 
or chronic setting. The SDF1/CXCR4 axis is considered to be vital for 
myocardial repair (Penn, 2009) but in terms of early cell functions 
necessary for improved outcome, i.e. attachment and spatial orientation 
at the injury site, SDF1 preconditioning does not significantly enhance 
them.  
Therefore, moving forward, it is important to understand the adhesion 
mechanisms involved in human MSCs before blindly testing potential 
preconditioning factors that have only been shown to work in other cell or 
species type.  
This focus will be on Neuropilin 1 (NRP1), as within the group there is 
experience with NRP1, but to date there has been no studies identifying 
it’s role for adhesion. NRP1 has been identified as having an important 
role in the adhesion of endothelial cells and migration of vascular smooth 
muscles cells (Pellet-Many et al., 2011) 
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Chapter 4 – The requirement for NRP1 for attachment, 
migration and vascular support capacity of human 
mesenchymal stem cells 
Introduction 
Bone marrow derived mesenchymal stem cells (MSCs) are multi-potent 
cells that are currently in clinical trials for cardiac repair. Their expansion 
capabilities and low immunogenic response are critical attributes for an 
allogenic therapy. Several studies have shown MSCs to be comparable to 
peri-vascular cells in both gene and protein marker expression and 
functionality (Covas et al., 2008b). The previous chapter failed to 
significantly improve the engraftment or pro-angiogeneic properties of 
MSCs or MNCs using SDF-1. Therefore, a better understanding of the 
underlying mechanism of engraftment is required for successful 
manipulation of the cells.  
It is important to understand mechanisms of attachment and migration for 
MSCs as animal models with MSCs have identified that few cells are 
retained the peri-infarct region after transplant (Pasha et al., 2008). 
Approximately 0.5-2% of transplanted cells are identified within this region 
with quantities diminishing over time (Shake et al., 2002). Research has 
recently focused on preconditioning cells exploiting the PI3K/AKt survival 
pathway with factors such as SDF-1 and HGF, however, the previous 
study was not able to replicate these results using SDF-1 (Gude et al., 
2008). Few studies have attempted to investigate adhesion and migratory 
response after preconditioning with most investigations analysing the 
effect on survival not function (Pasha et al., 2008). A protein that could be 
important for adhesion and migration in MSCs is Neuropilin 1 (NRP1). 
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NRP1 is a known co-receptor of Vascular Endothelial Growth factor 
receptors (VEGFRs) and Platelet-derived Growth Factor Receptors 
(PDGFRs) that is vital for attachment and migration in other cell types, 
including endothelial cells and neurons (Zachary, 2011). NRP1 is a type I 
transmembrane glycoprotein that regulates vascular development and is a 
key modulator of α5β1 integrin, a key adhesion molecule for attachment to 
fibronectin (Zacchigna et al., 2008). Studies in endothelial cells shown 
NRP1 has a role in angiogenesis (Valdembri et al., 2009),. MSCs express 
NRP1 and Ball et al, showed that in MSCs cross talk between NRP1 and 
PDGFRs controls migration, network formation and proliferation (Ball et 
al., 2010). However, the role of NRP1 for adhesion in MSCs is unknown. 
The present study shows that NRP1 is vital for fibronectin mediated 
adhesion, migration to PDGF-AA and has a role in the pro-vasculogenic 
function of MSCs 
Hypothesis 
NRP1 expression is required for effective attachment, migration and pro-
angiogenic function of bone marrow derived mesenchymal stem cells 
Material & Methods 
All methods and assays are as described in Chapter 2. However due to 
unavailability of MNC cell samples obtained from the REGENERATE trial 
this study will only be investigating passage 3 MSCs. This was chosen as 
3 passages allows for significant scale of MSCs while keeping functional 
properties that are lost as the MSCs mature; shown in the previous results 
chapter 
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The following methods are applicable to this chapter.  
 
Transfection with siRNAs 
The role of NRP1 was analysed by knocking down the gene expression, 
using siRNA. This method had been validated and optimised by Dr. Ian 
Evans from a collaborating lab at the Department of Cardiovascular 
Medicine, UCL, under direction of Prof. Ian Zachary. 
Transfection of MSCs was performed using Silencer® siRNA targted to 
NRP-1 (Life Sciences: #4912) or scrambled siRNA and Lipofectamine® 
RNAiMAX (Invitrogen, UK). MSCs were cultured in 6-well plated (Nunclon, 
UK) until 50-60% confluent.. Lipofectamine RNAiMAX was diluted with 
Opti-MEM (Life Sciences, UK) 1:50. siRNA and reagent were mixed and 
incubated for 20 minutes before adding 500µl of siRNA-Lipofectamine 
RNAiMAX complexes to each well. Cells were incubated at 37°C, and 
used experimentally after 24-48hrs.  
 
Western blot analysis 
Culture media was removed and cells were washed with dPBS then lysed 
with RIPA buffer (Invitrogen, UK) supplemented with protesase and 
phosphatase inhibitors (pierce Biotechnology, UK) Cell lysates were 
separated by electrophoresis on 10% SDS-PAGE gels, and 
electrotransfered onto PVDF memebranes for one hour at 140V. 
Membranes were blocked with 5% (w/v) non-fat dried milk in PBS 
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containing 0.1% tween 20, incubated with NRP-1 (C-19, Santa Cruz, USA) 
primary antibody (1:200) overnight at 4°C  and washed three times in PBS 
and incubated with horseradish peroxide labelled IgG for 1 hour. Proteins 
were detected using the ECL PLUS Western blotting detection system and 
Hyperfilm ECL (Amersham Biosciences). β-actin (1:500, Cat No:04-
116,Millipore, UK) was used as a loading control 
Gene expression 
For gene expression studies, after siRNA transfection and stimulation, 
cells were harvested and pelleted for qPCR as previously described in 
chapter 2.  Neuropilin 1 was accessed using the Quantitect NRP1 primer 
(Cat no. QT0023009, Quiagen) 
Static adhesion assay 
1x104 control MSCs (scrambled siRNA transfected) and MSCs target with 
NRP1 siRNA, were seeded onto 48 plates coated with BSA (2%w/v, 
Sigma), fibronectin (40µg/ml; R&D systems), vitronectin (2ug/ml;R&D 
systems), Collagen type I (2µg/ml; BD Biosciences). Plates were 
incubated at 37°C for either 5 or 20 minutes, then unattached cells were 
aspirated and wells were washed twice with dPBS. Images in 3 random 
fields of view in each well were counted at x4 magnification using a Nikon 
Eclipse microscope. Cells were counted using ImageJ software.  
Migration 
A modified Boydon chamber assay was used to assess cellular migration 
towards a chemotactic gradient. 1 x 105 control MSCs or NRP1 
Knockdown (KD) MSCs were seeded onto 8μm pore inserts (BD 
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Biosciences) with either serum free media, SDF-1 (100ng/ml; Biolegend) 
or PDGF-AA (50ng/ml; R&D Systems) in the lower compartment. Cells 
were allowed to migrate for 3 hours, after which non-migrating cells were 
removed from the upper surface of the membrane using a cotton swab. 
The membrane was fixed with 4% PFA and cells on the underside were 
stained with 0.25% crystal violet (Sigma) for 30 minutes. 3 random fields of 
view were imaged under x10 magnification and counted using ImageJ 
software 
 Wound healing assay 
Control MSCs and NRP1 KD MSCs were seeded onto a fibronectin coated 
12 well plate and allowed to reach confluence. Subsequently, a small 
scratch ‘wound’ was introduced to the cell monolayer using a 200µl pipette 
tip. The scratch site was imaged and the corresponding scratch location 
was imaged after 8 hours of incubation. The area of the scratch wound 
closed was calculated using ImageJ. 
Live labelling of MSCs and HUVECs 
To enable visual differentiation between the cell types in culture they were 
labelled with fluorescing probes with non overlapping emission 
frequencies. 
Adherent HUVECs were labelled by incubating with 10nM CellTracker™ 
green (Invitrogen, UK; C2925) at 37°C for 30 minutes before washing with 
culture medium. Adherent MSCs were labelled with DiO (Invitrogen,Uk) for 
20 minutes at 37°C before washing with culture medium.  
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Tubule formation assay 
Wells of a 96 well Nunc plate were coated with 50µl of growth factor 
reduced Matrigel® (BD Biosciences) and incubated for 1 hour at 37°C. 
After knockdown, cells were harvested and resuspended in EGM-2. 1 x104  
control MSCs, NRP1 knockdown MSCs or HUVECS were seeded in EGM-
2 medium (Lonza) and incubated for 18 hours. For quantification each well 
was imaged and cell branch points were counted using ImageJ. Each 
assay was performed in triplicate. 
To assess the interaction of MSCs and endothelial cells within a 3D matrix, 
5x103 HUVECs and control MSCs or NRP1 KD MSCs in a 1:1 ratio, were 
seeded together, and branch points were quantified as described. 
HUVECs added at 24 hours served as a control. 
In vitro endothelial network support assay 
To assess the ability of the MSCs to support a pre-existing endothelial 
network, MSCs were seeded onto a performed tubule network. In brief, 5 
x103 live stained with Celltracker™ (Invitrogen,UK) were seeded onto 
Matrigel. After 24 hours 5 x103 HUVECS control MSCs, or  NRP1 KD 
MSCs were seeded into each well. Images were taken of each well after 
72 hours. Total branch points were quantified using ImageJ software 
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Results
 
 
 
 
 
 
Figure 23 NRP1 knocked down in MSCs by siRNA. MSCs endogenously 
express NRP1 (A). MSCs were transfected with NRP1 targeted siRNA, or 
non specific control scrambled siRNA. 24 hours of transfection with siRNA 
knockdown was confirmed by ICC (A), western blot (B-C) and gene 
expression of NRP1 according to quantitative qPCR (D). β-actin was used 
as a loading control for the western blot. Scale bars are equal to 100nm. 
*=p<0.05 
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Figure 24 NRP1 plays a role in fibronectin induced attachment. 48 hours 
after transfection with either scrambled (control) or NRP1 siRNA MSCs 
were plated onto BSA (A) and fibronectin (B) coated wells for 5 and 20 
minutes. Results presented are cumulative data (A-B) from three different 
donors (C-E). Values are mean number of cells per field view ± SEM (n=3) 
.*=p<0.05 
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Figure 25 NRP1 not necessary for adhesion to collagen and vitronectin.  
48 hours after transfection with either scrambled (control) or NRP1 siRNA 
MSCs were plated onto type 1 collagen (A-D) and vitronectin -1 (E-H) 
coated wells for 5 and 20 minutes. Results presented are cumulative data 
(A,E) from three different donors. Values are mean number of cells per 
field view ± SEM (n=3) .*=p<0.05 
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NRP1 is important for adhesion to fibronectin 
MSCs were expanded from isolation in normal growth media that included 
DMEM, 10% FBS and 1ng/ml bFGF on tissue culture plates. To 
understand the mechanism that controls adhesion to different ECM 
proteins, NRP1 was knocked down in MSCs by transfection with a NRP1 
targeted siRNA. 24-48 hours after transfection MSCs were used in the 
experimental assays.   
Fibronectin, collagen type 1 and vitronectin 1 are typical ECM proteins, 
with fibronectin of particular interest as it is highly deposited in the infarct 
heart. MSCs were seeded onto BSA or fibronectin coated wells and 
allowed to adhere for 20 minutes. The short term adhesion assays showed 
that adhesion to fibronectin is significantly reduced by knockdown of NRP1 
(Figure 24B) but adhesion to other substrates is not affected (Figure 25 A 
and E). This is consistent with all MSC isolations except for X29 that has 
significant decrease in adhesion to vitronectin 1 after NRP1 knockdown 
(Figure 25G). 
Migration to PDGF-AA, but not SDF-1, is dependent on NRP1 
Having established that NRP1 has an important role in static attachment to 
fibronectin, chemotaxis towards 100ng/ml SDF1 and 50ng/ml PDGF-AA, 
was accessed over 3 hours (Figure 26A). Migration index was calculated 
to express the stimulated migration against random migration in the 
absence of the chemokines. Migration towards SDF1 was not affected by 
knocking down NRP1 compared to control MSCs (3.21±0.49 versus 
3.09±0.43, p>0.1)  (Figure 26B).  
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Exposure to PDGF-AA substantially enhanced migration of control MSCs 
compared to SDF-1 (17.97±4.67 vs 3.21±0.49). However, knockdown of 
NRP1 resulted in a significant reduction in migration (17.97±4.67 versus 
13.69±3.68) (Figure 26B). This relationship was observed for all 
independent isolations, although X27 had approximately double the 
number of migratory cells to PDGF-AA compared to isolations X29 and 
GX03 (Figure 26C-E). The control migrated MSCs to PDGF-AA appear to 
display more filopodia than the NRP1 knockdown MSCs (Figure 26A). 
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Figure 26 NRP1 has a role in PDGF-AA induced migration. 48 hours after 
transfection with either scrambled (control) or NRP1 siRNA MSCs were 
transferred to transwells and allowed to migrate for 3 hours to either serum 
free media, SDF-1 (100ng/ml), or PDGF-AA (50ng/ml). The transwell 
membrane were fixed and all non-migratory cells were scrapped off before 
the migratory cells were stained with crystal violet (Figure A). Scale bars 
equal 100nm. Results presented are cumulative data (B) from three 
different donors (C-E). Values are mean number of cells per field view ± 
SEM (n=3) .*=p<0.05 
NRP1 does not impact wound closure response 
Both control and NRP1 KD MSCs were grown in normal growth media to 
confluence on fibronectin coated dishes, scratched with a pipette tip and 
imaged at the start of the experiment and then again after 8 hours (Figure 
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27A). ‘Scratch area’ was measured for 0hr and 8 hour using Image J to 
determine closure percentage.  The percentage wound closure after 8 
hours was not affected by NRP1 knockdown (p>0.1) (Figure 27B). There 
was a large amount of variability in response to the scratch wound 
between independent donors. Wound closure for donor X27 was slower 
than for X29, where after 8 hours most wells in both groups exhibited full 
closure (Figure 27C-E) 
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Figure 27 NRP1 does not have an impact on wound healing response. 48 
hours after transfection with either scrambled (control) or NRP1 siRNA 
(control) MSCs were, and grown to confluency. Then a pipette tip was 
used to create a scratch, the closure of the scratch wound was observed 
over 8 hours (A). Dotted red line indicates scratch wound edge. Values are 
mean scratch wound closure ± SEM (n=3) (B-E). 
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Figure 28 The effect on NRP1 knockdown on network formation was 
examined using an in vitro Matrigel assay. MSCs were seeded onto the 
gel and incubated for 18 hours (A).. Results presented are the total the 
branch points formed through the entire well (B-E). *=p<0.05. Scale bar 
represents 100nm 
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MSCs form a tubule network in matrigel 
To test the hypothesis that MSCs have pro-angiogenic properties that are 
measurable in simple in vitro assays, several Matrigel-based assays were 
set up. MSCs were seeded either alone or in a co-culture with HUVECs to 
determine the requirement of NRP1 in cell to cell over 18 hours. 1 x104 
MSCs in EGM2 were seeded onto a thick matrigel gel coating (Figure 
28A). EGM-2 contains a number of growth factors and supplements 
including When NRP1 was knocked down, MSCs formed fewer 
branchpoints than control MSCs (Figure 28B), Moreover, NRP1 KD MSCs 
agglomerated at branch points (Figure 28A).  
MSCs stabilise an endothelial network in a pericyte-like function 
To understand how MSCs would interact with an endothelial network upon 
delivery to a physiological site, MSCs were seeded onto a pre-existing 
HUVEC network. MSCs were stained with a fluorescent marker, DiO 
(Figure 29A) and HUVECs with Celltracker (Figure 29B), to identify each 
cell type. HUVECs formed a lattice like network after 24 hours. When 
MSCs were added at this time point the network was stabilised for at least 
72 hours (Figure 29C). In contrast, the network was not stabilised when 
HUVECs or NRP1 knockdown MSCs were added (Figure 29H) and 
resulted in significantly decreased branch points. Live cell staining of the 
MSCs and HUVECs revealed physical interaction between the 2 cell types 
(Figure 29D-G) but this was diminished when NRP1 KD MSCs were used, 
with MSCs mostly seen agglomerated at branch points (Figure 29G). After 
72 hours the MSCs appeared to support the HUVEC network bridging 
between tubule forming endothelial cells (Figure 29F). 
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Figure 29 – NRP1 expression in MSCs is necessary to support an 
endothelial network. 48 hours after transfection with either scrambled or 
NRP1 KD siRNA MSCs were seeded onto a HUVEC network on a 
matrigel layer. The HUVEC network was created by seeding HUVECs in 
matrigel for 24 hours. Live cell staining of MSCs (A) and HUVECs (B) 
using fluorescent probes DiO (red) and Celltracker (green) respectively. 
Images were taken at 24 and 72 hours (C-E), Fluorescent images were 
taken at x4 (figure C-D) and x20 magnification (F-G). Scale bar represents 
100nm Results presented are normalised branch points of the entire well 
to their respective quanity at 24 hours + SEM (H-K). *=p<0.05. 
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Endothelial cells form tubules on a MSCs monolayer 
HUVECs were seeded onto a MSC monolayer and probed for PECAM-1, 
an endothelial marker. They formed tubule like structures on the control 
MSCs (Figure 30C) but not on top of the NRP1 KD MSCs where they 
formed random structures and agglomerates (Figure 30D). Phase contrast 
images showed no structural appearances (Figure 30A-B) 
 
Figure 30 HUVECS form networks on a monolayer. 
MSCs, knockdown and control, were grown to confluency in 24 well 
plates. HUVECs were added onto the monolayer and incubated for 72 
hour (A-B). Cells were then fixed and probed for PECAM-1 by 
immunocytochemistry (C-D). Images were taken at x4 magnification. Bars 
represent 100um 
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Discussion 
In the previous chapter, it was shown that SDF-1 was unable to improve 
the engraftment responses of bone marrow derived mononuclear and 
MSCs. To improve the functional characteristics of cell therapy candidates 
the mechanism underpinning attachment and migration needed to be 
understood. One key limitation in this chapter was the lack of availability of 
mononuclear cells from the clinical trial to perform additional analysis. 
However, it may have been difficult to work with mononuclear cells as 
maintaining them in suspension culture for the duration of the knockdown 
protocol would have substantially reduce cell viability and impacted on the 
validity of the data.  
Identifying the proteins that are crucial for attachment, migration and 
general tissue support at sites of ischemic injury is fundamental to the 
improvement of cell therapy strategies for myocardial infarction. Integrins 
are known surface receptors that interact with ECM ligands but there are 
other surface receptors with less characterised roles. The function of 
NRP1 has been much investigated in other cell types such as endothelial 
and smooth muscle cells, but only one to date in MSCs (Ball et al., 2010; 
Pellet-Many et al., 2011; Valdembri et al., 2009). In this study the 
functional role of NRP1 during attachment, migration and vascular support 
responses by MSCs was investigated.  
This study showed that NRP1 is important for attachment of MSCs 
specifically to fibronectin, but not to other tested ECM components, and is 
in part required for migration towards PDGF-AA, but not SDF1. Also, the 
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ability for MSCs to support an endothelial network in vitro is diminished in 
the absence of NRP1 
MSCs endogenously express NRP1, and so to assess its effect on 
functional characterstics it was knocked down using siRNA. 
Immunofluroscence imaging revealed that although NRP1 is described as 
a transmembrane protein the majority is expressed intracellularly. This is 
consistent with, a recent study by Ball et al study who also show that 
MSCs express NRP1 and similar to immunofluroscence images presented 
in this chapter, NRP1 was mainly located intracellularly (Ball et al., 2010). 
After myocardial infarction, fibronectin is deposited within the peri-infarct 
zone of the myocardium (Ip et al., 2007). MSCs rapidly adhere to 
fibronectin via integrins (primarily 51). However, given the overall hostile 
environment in the post-infarct heart, cell attachment, and survival are low 
(Pasha et al., 2008). By improving these ‘engraftment’ characteristics, has 
the potential to improve MSC survival and therapeutic efficacy. 
Other ECM components within the myocardium also include type 1 
collagen and vitronectin, as these are also ECM components within the 
myocardium. The different ECM proteins have have key interactions with 
different integrins receptors: fibronectin is associated with α5β1 and αVβ3; 
victronectin 1 with α3β1; and type 1 collagen with α1β1/ α2β1(Covas et al., 
2008b).  
After successfully knocking down NRP1 using siRNA, the ability of MSCs 
to attach to fibronectin significantly decreased, but attachment to type I 
collagen and vitronectin was not affected. This is not surprising, as in 
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endothelial cells NRP1 was previously reported to interact with active α5β1 
at sites of adhesion (Valdembri et al., 2009). Other studies on MSC 
adhesion reported that α5β1 significantly increased the tyrosine 
phosphorylation of PDGFR following ligation with fibronectin (Veevers-
Lowe et al., 2010). In spite of the evidence to demonstrate that NRP1, 
α5β1, and PDGFRs are implicated in attachment to fibronectin, however 
there are no studies have confirmed the mechanism of their combined 
interaction. Knockdown of NRP1 did not completely impair adhesion of 
MSCs to fibronectin. While integrin α5β1 is a key integrin for fibronectin, 
αVβ3 also plays an important role and there is no current evidence to 
show interaction with αVβ3 and NRP1 (Ip et al., 2007). Therefore, 
functional rescue by αVβ3 may explain why attachment was not 
completely impaired 
PDGF-AA is released post myocardial infarction, as is SDF-1 (Wallace et 
al., 1998, {Ip, 2007 #90)}. Therefore, the importance of NRP1 for migration 
in response to NRP1 and PDGF-AA was investigated using a transwell 
chemotaxis assay. The first important observation was that MSC migration 
towards PDGF-AA was much greater than towards SDF-1. Secondly, 
NRP1 knock-down resulted in significantly decreased migration towards 
PDGF-AA but not SDF-1. This corroborates with a previous study that 
assayed the chemotactic effects of 16 different growth factors and 
chemokines on human bone marrow-derived mesenchymal cells, where 
PDGF was the most potent and chemokines such as SDF-1 invoked 
limited responses (Ponte et al., 2007).  
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The link between NRP1 and PDGF-AA has been documented previously. 
Ball et al also showed that knockdown of NRP1 decreased migration of 
MSCs to PDGFR-AA (Ball et al., 2010). NRP1 is also important for 
migration of other cell types including endothelial cells and vascular cells 
towards PDGF-AA (Pellet-Many et al., 2011; Valdembri et al., 2009). The 
inhibition of PDGF-AA responsiveness due to NRP1 knockdown is 
mediated, at least in part, by p130cas (Pellet-Many et al., 2011). The cross 
talk between NRP1 and PDGFR that controlled not only migration, but 
also signalling and proliferation confirming that NRP1 has multi functional 
roles (Ball et al., 2007). Like adhesion, for migration to PDGF there is 
interplay between α5β1 integrin activated PDGFRs.  
Despite a significant decrease in cells attached to fibronectin, no effect 
was observed in a wound response assay on fibronectin after NR1 
knockdown. This was susprising, as previous studies reported that pre-
treatment of endothelial cells with recombinant NRP1 significantly 
improved wound repopulation (Uniewicz et al., 2012). Moreover, NRP1 
mediated endocytosis  and recycling of α5β1 integrin to the cell’s leading 
edge during endothelial migration on fibronectin has been reported 
(Valdembri et al., 2009). However, there are multiple limitations to this 
assay that may explain our inability to delineate a difference. Firstly, the 
‘rate’ of wound repopulation was not determined in real time, rather single 
photomicrographs were taken at the start of the assay and at 8hrs. 
Secondly, due to the manual production of ‘scratch’ wounds, 
reproducibility is poor, as reflected by large standard deviations. Thirdly, 
the fibronectin layer may be partly or completely removed when the cell 
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monolayer is scratched. Finally, there may be no difference when NRP1 Is 
knocked down simply because migration is initiated via functionally 
competent αVβ3 and α8β1, which are not been reported to be dependant 
on NRP1 (Charo et al., 1990; Marshall et al., 1995) 
Tubule formation assays utilising ECM substrates rich in basement 
membrane proteins, such as Matrigel, have been extensively utilised. All 
assays in this chapter were conducted using EGM-2 a proprietary growth 
media supplemented with pro-angiogenic factors including VEGF, EGF, 
and IGF at undisclosed concentrations. MSCs lacking the supplement, no 
vessel-like networks were observed, confirming the inter-dependence on 
these factors and the Matrigel. The formation of tubules seen when plating 
WT MSCs confirmed the ability of MSCs to respond to vascular stimulus 
and represents a balance between cell-cell interactions and cell extension 
and migration across the Matrigel. When NRP1 fewer branches were 
formed, consistent with findings from Ball et al (Ball et al., 2010) In 
addition NRP1 knockdown, did not eliminate tubule-like networks 
completely, but cell clustering around branch points was noted.  
Vascular support is hypothesised to be a potential mechanism of action of 
MSCs on delivery to ischemic tissues. This is particularly desired in an 
indication like myocardial infarction as not only are cardiomyocytes lost, 
but also the vasculature that is needed to support the cells in the peri-
infarct region. Therefore, understanding how MSCs interact with a pre-
existing endothelial network is crucial. Using a modified method from a 
previous study with dental pulp cells (Dissanayaka et al., 2012), MSCs 
were seeded onto a pre-exisiting endothelial network and incubated for a 
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furthur 48 hours. Direct co-culture of MSCs increased the longevity of pre-
exiting. However, when NRP1 was knocked down, the network 
substantially diminished. Adding HUVEC alone to pre-existing vessel like 
structures did not support vessel stabilisation did not occur. The MSCs 
were observed to bridge between the endothelial cells and make physical 
contact in a manner akin to pericyte cells, a phenomenon that was lacking 
in the absence of NRP1. This provides evidence of a mechanism of pro-
vascular support by MSCs, governed not solely by paracrine factors, and 
dependant on direct contact and interaction with endothelial cells.  
When HUVECs were co-cultured on a monolayer of MSCs distinct 
PECAM-1 positive vessels were formed. However, HUVECs cultured on 
the NRP1 knockdown MSCs tended to form more sporadic and less 
tubules-like structures, reinforcing the importance of NRP1 for MSC cell to 
cell contact with endothelial cells for tubule formation. 
As identified in the previous chapter, in spite of the inter-donor variability 
(notably in the wound repopulation assay), the experimental observations 
were, largely, highly conserved between different donors. It was notable 
that isolation X27 had the highest migratory response to PDGF-AA, 
diminished response in the wound assay, and high branch count in the 
Matrigel assay, Many other studies have only identified donor differences 
for proliferation and differentiation potential (Lo Surdo and Bauer, 2012).  
Conclusion 
In conclusion, data in this chapter has revealed that NRP1 is important for 
adhesion to fibronectin, migration to PDGF-AA, and vascular support 
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responses. This data provides the foundation for exploration of novel 
methods by which to stimulate and enhance engraftment of MSCs at 
physiologic sites. Continuation of this research, in the next chapter, 
focused on determining whether NRP1 can be up-regulated by 
preconditioning the cells, using a strategy that is accessible to cell therapy 
bioprocessing. 
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Chapter 5 – Effect of hypoxia and bFGF on Neuropilin 1 
expression, cell retention responses and pro-vasculogenic 
properties of MSCs 
 
Introduction 
 
Preconditioning strategies have been used in multiple animal AMI models 
to successfully improve cardiac output, including pharmacological 
stimulation, or environmental stimulus such as hypoxia (Pasha et al., 
2008) (Wisel et al., 2009). The purpose of preconditioning is typically to 
activate endogenous pathways that have multi-factorial effects including 
increased survival, enhanced cytokine release, or improve homing to the 
physiologic site of interest. 
Hypoxic preconditioning, has been found to increase MSC survival in 
ischemic environments after transplantation. In these low oxygen 
conditions VEGF and HGF, important growth factors for angiogenesis and 
cytoprotection, become upregulated in MSCs (Chang et al., 2012). As data 
in chapter 4 indicates NRP1 is important for cell adhesion, we wanted to 
determine whether it is regulated by oxygen tension. It is already known 
that the effect of hypoxia on NRP1 expression is cell dependent, so whilst 
NRP1 In endothelial cells and embryonic cells is upregulated by hypoxia, it 
is downregulated in neuroblastoma cell lines (Brusselmans et al., 2005; 
Misra et al., 2012; Ottino et al., 2004) 
NRP1 expression is regulated by bFGF in vascular smooth muscles cells 
that undergo increased chemoxtaxis to VEGF-A in a NRP1 dependent 
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fashion (Liu et al., 2005). Furthermore, bFGF, along with IGF-1 and BMP-2 
illict a pro-survival effect of MSCs (Hahn et al., 2008). Treatment with this 
growth factor combination enhanced the MSC cardiac differentiation 
efficiency and cytoprotection of co-cultured adult cardiomyocytes (Hahn et 
al., 2008). Importantly, cytoprotection was dependent on gap-junction 
communication with cardiomyocytes, demonstrating the need for direct 
interaction between the MSCs and cardiomyocytes, rather than by a 
paracrine mechanism. Similarly, Khan et al preconditioned MSCs isolated 
from diabetic mice with a combination of IGF-1 and bFGF and showed 
enhanced cell survival, proliferation, motility and angiogenic potential 
compared to untreated cells or cells treated with single growth factor 
(Khan et al., 2011). Therefore, whether bFGF can enhance NRP1 and 
improve functional characteristics attributable to NRP1 is an interesting 
research question 
The previous chapter showed that NRP1 is an important protein in MSCs 
for adhesion to fibronectin, migration to PDGF-AA and vascular support 
responses. In the present study, strategies to upregulate NRP1 expression 
using hypoxia and bFGF were investigated, and the effect on the MSC 
adhesion, migration and cytokine release was quantified 
 
Hypothesis 
Enhancing the expression of NRP1, by preconditioning the MSCs, is 
positively correlated with improved adhesion, migration of MSCs and 
vascular support responses. 
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Materials & Methods 
 
Culture of MSCs and functional assays were as described in Method and 
materials. Except for the following additions and adaptations 
bFGF stimulation 
MSC experimental groups were set up as follows 
1. Control MSCs (scrambled siRNA), passage 3, unstimulated 
2. Control MSCs (scrambled siRNA), passage 3, stimulated for 12 
hours with 10ng/ml bFGF 
3. siRNA NRP1 knockdown MSCs, passage 3, unstimulated 
4. siRNA NRP1 knockdown MSCs, passage 3, for 12 hours with 
10ng/ml bFGF 
Gene expression 
For gene expression studies, after siRNA transfection and stimulation, 
cells were harvested and pelleted for qPCR as previously described in 
chapter 2.  Neuropilin 1 was accessed using the Quantitect NRP1 (Cat no. 
QT0023009, Quiagen) 
 For the differentiation assays, actinin-associated LIM protein (ALP) and 
peroxisome proliferator-activated receptor gamma (PPARg) Quantitect 
primers (Cat no. QT01905099 & QT0005468, Quiagen) were used as 
according to manufacturer’s instructions in the two step qPCR protocol 
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Migration 
A modified Boydon chamber assay was used to assess cellular migration 
towards a chemotactic gradient. 1 x 105 MSCs were seeded onto 8μm 
pore inserts (BD Biosciences) with either serum free media (control) or 
PDGF-AA (100ng/ml; R&D Systems) in the lower compartment. Cells were 
allowed to migrate for 3 hours, after which non-migrating cells were 
removed from the upper surface of the membrane using a cotton swab. 
The membrane was fixed with 4% PFA and cells on the underside were 
stained with 0.25% crystal violet (Sigma) for 30 minutes. 3 random fields of 
view were imaged under x10 magnification and counted using ImageJ 
software 
 
Cytokine release 
MSCs were seeded at 1 x 104 in 6 well plates in duplicate for each 
experimental group. After the siRNA transfection protocol, as described in 
chapter 4, groups 2 and 4 were treated with 10ng/ml bFGF. Then media 
for all cells was replaced with normal MSC growth media with only 1% 
FBS. After 24 hours conditioned media was obtained and measured using 
commercially available Quantikine® enzyme linked immunosorbent 
(ELISA) assays for VEGF, IL-6, HGF, and PDGF-AA (DVE00, D6050, 
DHG00, DAA00B; R&D Systems). Each measurement was standardised 
to reference concentrations of protein as per manufacturer’s instructions. 
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Proliferation 
To investigate the proliferation effect of bFGF over 24 hours, 1x104 MSCs 
were seeded in 96 well plates. The cell number was measured using Cell 
Counting Kit-8 (Dojindo, Japan). MSCs were mixed with 10µl of CCK-8 
solution per well and incubated for 1 hour at 37°C. The plate was then 
read at an absorbance of 450nm using a microplate reader. Each 
experimental group was repeated for three different isolations in triplicate 
wells. 
 
Results 
 
NRP1 expression differentially regulated by hypoxia and bFGF 
In the previous chapter, we reported that NRP1 has a role in optimised cell 
attachment and migration. Here we assessed the effect of hypoxia on 
NRP1. A few studies have shown NRP1 to be over-expressed in different 
cell types by a number of strategies, including hypoxia preconditioning and 
bFGF stimulation (Liu et al., 2005). Using mRNA quantification, we found 
that low oxygen significantly reduced NRP1 expression in MSCs after 1 
hour (p=0.006) and furthermore at 24 hours in 2% oxygen (Figure32A). 
The next strategy was to stimulate the MSCs with 10ng/ml bFGF for 12 
hours. mRNA expression of NRP1 was significantly over-expressed in 
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MSCs (Figure 32A). This was consistent in all isolations used (Figure 
32B). 
 
 
 
 
 
 
 
 
Figure 31 - NRP1 is down regulated by hypoxia 
MSCs were put in a hypoxic chamber purged with 2% oxygen and 
incubated for 1 or 24 hours, or in control conditions of 20% oxygen. Cells 
were harvested and the mRNA isolated. Results presented are cumulative 
data (A) from three independent donors (B-D). Values =Gene expression 
for NRP1 analysed by qPCR and normalised to GAPDH & control group ± 
SEM (n=3) *=p<0.05  
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Figure 32 - NRP1 is upregulate in MSCs by bFGF 
MSCs were stimulated with 10ng/ml bFGF for 12 hours. Cells were 
harvested and the mRNA isolated. Results presented are cumulative data 
(A) from three independent donors (B-D). Values =Gene expression for 
NRP1 analysed by qPCR and normalised to GAPDH & control group ± 
SEM (n=3) *=p<0.05 
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Stimulation with bFGF has no effect on tri-lineage differentiation 
Tri-lineage differentiation, post bFGF stimulation, was observed in 
classical differentiation assays and gene expression studies. In parallel 
experiments, the impact of NRP1 was also observed with NRP1 KD 
MSCs.  
The osteogenesis protocol showed no significant difference by stimulation 
with bFGF or knockdown of NRP1, both phenotypically (Figure 33A-D) and 
gene expression for an osteogenic gene, ALP (Figure 33E).  
Stimulation with bFGF had no effect on number of cells with oil red O 
stained clusters (Figure 34A-D) and PPARg expression, an adipogenic 
gene (Figure 34 E). However, significantly less MSCs knocked down for 
NRP1 were oil red O positive than control cells (Figure 34A-D). 
Knockdown of NRP1 did not effect the expression of PPARg (Figure 34F). 
All experimental groups displayed similar phenotype in the 
chrondrogenesis classical assay, staining blue with Alcian Blue (Figure 
34A-D). 
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Figure 33 - NRP1 or FGF stimulation have no observed effect on 
osteogenic capacity. MSCs in all experimental groups were incubated in 
osteogenic inducing media. After 14 days MSCs were fixed and stained 
with alizarin red S. Images were taken at x4 magnification and scale bars 
represent 100µm (A-D). After 24 hours, cells were harvested and mRNA 
was isolated. Values = Average normalised expression for ALP analysed 
by qPCR and normalised to GAPDH & control group ± SEM (E) (n=3) 
*=p<0.05 
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Figure 34 - Knockdown of NRP1 decreases adipogenic capacity 
48 hours after transfection with either Nrp1 siRNA or scramble siRNA, 
MSCs were stimulated with bFGF or unstimulated (control) for 12 hours 
and incubated with adipogenic inducing media. Cells were fixed after 14 
days and stained with 1% oil red O solution. All images were taken at x4 
magnification. Scale bars represent 100µm (A-D). Results were the mean 
+ SEM of average number of cells per field view containing lipid clusters ± 
SEM (n=3) (E). After 24 hours, mRNA was isolated. Values = Average 
normalised expression for PPARɣ analysed by qPCR and normalised to 
GAPDH & control group ± SEM (F) (n=3) *=p<0.05) 
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Figure 35 – NRP or bFGF have no observed effect on chondrogenic 
capacity  
48 hours after transfection with either Nrp1 siRNA or scramble siRNA, 
MSCs were stimulated with bFGF or unstimulated (control) for 12 hours 
and incubated incubated with chondrogenic media for 14 days. Cells were 
then fixed and stained with Alcian blue. Images were taken at x4 
magnification. Scale bars are equal to 100µm (A-D) 
 
Adhesion to fibronectin decreased in hypoxic conditions, but is 
rescued by stimulation with bFGF 
To mimic the environment of the ischemic heart, an in-vitro assay using 
fibronectin as an ECM substrate and different oxygen tensions (normoxia 
& hypoxia) were used for an MSC adhesion assay. Cells were seeded 
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onto fibronectin, or a control substrate of tissue culture coated with BSA. 
In ambient oxygen levels, bFGF increased cell attachment (p=0.001; figure 
36A) NRP1 KD MSCs underwent decreased attachment to fibronectin, 
and stimulation with bFGF was not able to rescue this effect (Figure 36A). 
In hypoxic conditions, cell attachment was decreased but this effect was 
rescued with bFGF preconditioning to that of control levels in ambient 
oxygen (Figure 36A). This trend was reproduced in all donor isolations 
used except for X33, which had no significant reduction adhesion to 
fibronectin in hypoxia (Figure 36B). These results highlight the importance 
of NRP1 to bFGF stimulated adhesion of MSCs to fibronectin 
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Figure 36 – bFGF increases adhesion of MSCs in hypoxia 
48 hours after transfection with either Nrp1 siRNA or scramble siRNA, 
MSCs were stimulated with bFGF or unstimulated (control) for 12 hours 
and seeded BSA or fibronectin (FN) coated wells. Results presented are 
cumulative data (A) from three independent donors (B-D). Values = mean 
number of cells per field view ± SEM (n=3), *=p<0.05 
 
Migration is not affected by oxygen tension or bFGF stimulation 
 
Oxygen tension had no significant effect on the migration of MSCs (Figure 
37A). The MSCs, control or stimulated, were seeded into transwells and 
exposed to PDGF-AA. The chemotaxis of MSCs to PDGF-AA had shown 
to be NRP1 dependant. As shown previously, migration was decreased 
when NRP1 was silenced. However, no additional effect was observed by 
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prestimulating the MSCs. Also, there was no difference in number of cells 
migrated in 20% versus 2% oxygen. 
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Figure 37 Hypoxia or FGF does not effect MSC chemotaxis to PDGF-AA. 
MSCs were transferred to transwells and exposed to 50ng/ml PDGF-AA 
for 3 hours. Non-migratory cells were scrapped off and migrated cells on 
the membrane were stained with crystal violet. Images were taken at x10 
magnification in 3 random field views and counted using ImageJ software. 
Results presented are cumulative data (A) from three independent donors 
(B-D). Values = mean migration index ± SEM (n=3), *=p<0.05 
 150 
MSC proliferation rate not affected by bFGF stimulation 
The effects of NRP1 knockdown on MSC proliferation was investigated in 
bFGF stimulated and control experimental groups. After stimulation with 
bFGF, media was replaced with 1% serum growth media and incubated 
for 24 hours. No significant increase with bFGF-stimulated groups was 
observed (Figure 38A). This trend was consistent for all isolations (Figure 
38B-D) except for X35 that had higher average absorbance value for 
knockdown MSCs (Figure 38C)  
 
 
 
 
Figure 38 – Stimulation with bFGF does not significantly affect proliferation 
of MSCs. Following SiRNA knockdown with either Scr control or target 
NRP1 SiRNA, the effect of bFGF stimulation was analysed after 24 hours. 
CCK-8 was added to supernatant and measured using a plate reader at 
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450nm. Results presented are cumulative data (A) from three independent 
donors (B-D). Values = mean absorbance ± SEM (n=3),  
 
Stimulation increases the MSC cytokine release profile 
 
MSCs are hypothesised to release cytokines, such as VEGF, HGF, PDGF-
AA and IL-8 that activate pro-angiogenic, survival pathways and account 
for their immunomodulatroy capacity. The MSC protein release profile was 
investigated using ELISA after 24 hours for each experimental group. 
VEGF was significantly increased in the groups that were stimulated 
(p<0.01); however as there was no difference between control MSCs and 
NRP1 KD groups, VEGF release was not NRP1 dependant (Figure 39A). 
This trend was consistent in all isolations although stimulation had a 
greater VEGF release in X34 (Figure39B).  
IL-8 was significantly increased in all isolations except in X35 that had 
lower values of Il-8 that the standardised range. Isolation X34 had higher 
values of Il-8 than the standardised range (Figure 39G). 
No effect in HGF release was observed in experimental groups (Figure 
39I). Isolation GX05 had a lower release of HGF than the other 2 
isolations (Figure39J). No PDGF-AA was detected from any MSC isolation 
(no data shown). 
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Figure 38 - FGF induces increased VEGF release of MSCs. 
MSCs, either control or NRP1 knockdown were exposed to 10ng/ml bFGF 
for 12 hours, then media was changed to 1% FBS in DMEM. After 24 
hours media was removed and analysed for VEGF (A-D), IL-8 (E-H), and 
HGF (I-L) by ELISA. No PDGF-AA was detected in any isolation. Results 
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presented are cumulative data (A,E,I) from three independent donors. 
Values = Average protein concentration ± SEM (n=3), *=p<0.05 
 
Discussion 
The previous chapter identified NRP1 as an important protein for 
attachment and migration and assays were developed to ascertain the 
functional characteristics of the cells. Passage 3 MSCs proved to be 
optimal for achieving suitable cell quantities without diminishing cell 
function, as culture to passage 5 proved to reduce the migratory capacity 
of the MSCs. The assays developed aim to more closely replicate the 
physiological environments of the infarct heart. 
Preconditioning MSCs with molecules that might stimulate or enhance 
their activity is an exciting candidate bioprocessing strategy to prime 
MSCs and achieve optimal product quality. Improving both attachment and 
pro-vasculogenic capabilities can lead to a synergistic effect in the sense 
that the more cells that are retained in the region of interest with a higher 
potency, the greater the therapeutic response. This would be of benefit to 
a bioprocess as lower therapeutic dose can be used.  
Although genetically enhancing stem cells has been very successful in 
pre-clinical trials there is still much safety & technical concerns associated 
with this approach (Bonaros et al., 2008; Penn & Mangi, 2008). An ex-vivo 
pharmacological preconditioning using factors that are already licensed for 
use in humans is a more attractive strategy. This study investigated the 
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effect of upregulation of NRP1 on adhesional, migratory and cytokine 
responses. 
This is the first study to investigate the effect of upregulation of NRP1 on 
the biological function of MSCs. NRP1 expression and regulation has not 
been well characterised in MSCs, but it is known to be vital for 
angiogenesis in endothelial cells (Valdembri et al., 2009). Also, in cancer it 
is involved in tumour growth and invasion (Stephenson et al., 2002) as 
NRP1 over expression in prostate carcinoma is correlated with metastatic 
potential and tumour aggressiveness (Latil et al., 2000). 
NRP1 was increased at both gene and protein level after stimulation with 
bFGF, while hypoxia caused NRP1 expression to decrease in both acute 
and longer term, 24 hour, time periods. In addition to upregulating NRP1, 
bFGF has shown to activate the PI3K/Akt signalling pathway that has a 
core regulatory role in MSC survival, proliferation, migration and 
differentiation (Ahn et al., 2009 {Chen, 2013 #470; Chen et al., 2013). 
Therefore, preconditioning with bFGF was used for the rest of the study. 
To validate the MSCs as multipotent, tri-lineage differentiation protocols 
were performed on knockdown and preconditioned MSCs. To which all 
demonstrated tri-lineage differentiation to some extent. Increase in 
osteogenic potency has been previously observed when in long term 
culture using high concentration of bFGF, whereas the short term 
stimulation in this study had no effect either phenotypically or on ALP gene 
expression (Hanada et al., 1997). However, knockdown of NRP1 
significantly reduced the number of oil red O positive lipid clusters that are 
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an indicator of adipocyte like cells. As no change was observed in PPARg, 
an early adipogenic marker, NRP1 is more likely to influence the maturity 
of preadipocytes to lipid containing adipocytes (Cristancho and Lazar, 
2011). This role of NRP1 for adipogenic differentiation has yet to be fully 
investigated. 
bFGF preconditioning significantly improved attachment of MSCs in both 
normoxia and hypoxia. Significantly fewer MSCs attached to fibronectin in 
a hypoxic environment than normoxia. This response was rescued by 
preconditioning the cells with bFGF. As stimulation of NRP1 knockdown 
MSCs did not result in enhanced adhesion as occurred for control MSCs 
this is likely to be an NRP1 dependent mechanism. The hypoxic conditions 
mimicked physiological sites, therefore improving adhesion in these 
conditions would be of great benefit for a therapeutic candidate for cell 
therapy. As many transplanted cells do not survive or engraft, 
enhancement of this response could improve clinical end outcomes (Kean 
et al., 2013).  
In vascular smooth muscle cells, upregulation of NRP1 resulted in 
enhanced migration (Liu et al., 2005). However, in this study no further 
increase in migration to PDGF-AA was observed for MSCs.  
Biological function assays are vital for understanding the quality attributes 
of MSCs products for a therapeutic indication. The results show that in 
different isolations, from healthy donors, there is a large difference in 
cytokine release. MSCs have been proposed to act as 'Medicinal 
Signalling Cells' (Koutsoumbelis and Grande, 2013), and therefore, on this 
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premise an ideal MSC candidate for therapy could be decided on the basis 
of secreted factors. One such factor is VEGF which is cited in many 
studies for it's pro-angiogenic effect (Gnecchi et al., 2008b; Wang et al., 
2006). On average, bFGF stimulated MSCs produced approximately 2 fold 
more VEGF than unstimulated cells. This was independent of NRP1, as 
the same effect was observed in the knockdown MSCs 
Studies have shown that in addition to VEGF, HGF is cardio-protective 
and can maximise beneficial effect of MSC following cardiac injury (Deuse 
et al., 2009). However, HGF release was not affected by stimulation with 
bFGF. This is contrary to another study, using adipose derived stromal 
cells, which showed a substantial increase in HGF after culturing with 
10ng/ml bFGF (Suga et al., 2009).  
Another use of MSCs has been for their immunomodulatory properties in 
indications such as graft versus host disease. For this a high release of IL-
8 such as X34 would be highly desired. There was a substantial difference 
between the release profiles of individual isolations, with an approximate 
100-fold difference between X35 and X34. Proliferation was not affected 
by preconditioning during the same time period for which the ELISA 
protocol was performed. Therefore, change in proliferation did not account 
for any change in growth factor release.  This response to bFGF 
stimulation is consistent with another study that shows a significant 
increase long term, +6 days, but not in shorter time periods (Suga et al., 
2009) 
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Conclusion 
 
In conclusion, this study showed that ex vivo preconditioning MSCs with 
bFGF increases adhesion of cells in hypoxia in a NRP1 dependent 
mechanism. Preconditioning also enhanced release of VEGF, a potent 
angiogenic growth factor, independent of NRP1. A non-genetic approach 
of enhancing the MSCs performance could have a synergistic positive 
effect for use in therapy. If more, higher potency cells can engraftment 
after therapeutic application, then fewer cells will be needed to achieve the 
same functional output. This is highly advantageous for cell therapy 
bioprocessing. 
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Chapter 6 - Discussion 
 
Heart failure is a global problem with no cure, contributing to considerable 
costs to the economy. Although improvements in pharmaceutical and surgical 
interventions have increased patients’ survival after myocardial infarction, the 
number of patients progressing to congestive heart failure has increased for 
which there is no cure, only symptomatic control, has increased (Pearson-
Stuttard et al., 2012).  Cell therapies are an emerging class of therapeutics 
that have the potential to address current unmet clinical needs including heart 
failure. Human bone marrow MNCs and MSCs are both candidates for 
cellular therapy that are in late phase clinical trials around the world. 
However, results from these have, so far, been modest (Clifford et al., 2013). 
Animal studies have shown that cellular survival and engraftment at the site 
of delivery is low and this possibly explains why clinical improvements are 
limited (Freyman et al., 2006a). Developing assays that more closely reflect 
the in vivo environment and cell activation strategies that improve the 
retention of cells should enable better understanding mechanism of action 
and potency in addition to assay development to accurately measure product 
quality. Then the clinical potential of these therapies can be more widely 
achieved.  
The proposed function of bone marrow derived stem cells in the ischemic 
myocardium is widely debated (Mirotsou et al., 2011). However, an attractive 
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proposed mode of action relates to the cells’ vascular support capacity, due 
to the ischemic nature of the injury sites. The purpose of this thesis was to 
employ in vitro assays that mimicked the physiological environment of the 
peri-infarct regions to quantify adhesion, migration and pro-vasculogenic 
properties of the cells.  These assays could then be used to assess the effect 
of preconditioning cells with various biochemical or physiochemical factors as 
a tool for enhancing these critical functions. Both bone marrow derived MNCs 
and MSCs were used in this study. The MNCs were obtained from patients in 
the REGENERATE clinical trial, while the MSCs were cultured from using 
cryogenically preserved frozen bone marrow aspirates from healthy donors.  
The initial hypothesis tested was that by preconditioning the MSCs and MNCs 
with SDF-1 would enhance the above biological function of the cells by 
increasing cell attachment and migration responses, based on the fact that 
SDF-1 is a chemoattractant that mobilises MSCs via CXCR4, which in turn is 
known to activate integrins (Peled et al., 2000). The other critical reason for 
examining SDF-1 was based on reported observations from Pasha et al who 
found that in response to SDF-1  rat MSC retention in an experimental infarct 
model was increase resulting in improved vascular restoration and decreased 
infarct size (Pasha et al., 2008). Unfortunately, the SDF-1 preconditioning 
strategy that was successful for rat AMI using rat MSCs was not reproduced 
in assays developed in this thesis using human MSCs and MNCs. This may 
be due to diminished expression of CXCR4, the corresponding receptor of 
SDF1, as long-term expansion culture has been shown to abrogate CXCR4 
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expression in hMSCs (Jones et al., 2013; Wynn et al., 2004). No effect was 
observed after SDF-1 preconditioning for either cell type. Both MSCs and 
MNCs adhered strongly to fibronectin, but this was substantially diminished in 
low oxygen tensions. The MSCs did demonstrate vasculogenic potential by 
forming tubule-like structures when cultured on Matrigel without differentiating 
into endothelial cells.  
Using a hypoxia chamber I was able to reproduce low oxygen conditions (2% 
oxygen) to reflect that of the physiologic sites that the cells would be 
transplanted into. In these reduced oxygen conditions adhesion of MSCs and 
MNCs was significantly impaired when compared to ambient oxygen levels 
typical of standard culture conditions used for cell bioprocessing. This has 
significant implications for clinical therapy because processing and quality 
attributes and survival capacity on delivery to a physiologic inury site and may 
explain why so few residual cells are retained after dcelivery in animal AMI 
models, as most process conditions do not reflect the variable physiological 
conditions characteristic of injury sites. With reduced engraftment in the 
region of interest there is less opportunity to infer therapeutic benefit, via 
trophic factors or direct interaction with vascular networks and 
cardiomyocytes.  
The lack of availability of the MNCs from the REGENERATE-IHD clinical trial 
discontinued their use in the rest of the thesis. Regardless, there is less 
scope for a bioprocess step for MNCs, as most preconditioning protocols are 
for long term stimulation that would significantly impair the functional viability 
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of the cells. MSCs provide a more scalable approach, amenable to cell 
bioprocessing, as the cells can be expanded to desired quantities and cell 
characteristics such as surface markers, migration potential or cytokine 
production can be easily measured. The MSCs used were cryogenically 
preserved for a repeated experiments and future use. This is consistent with 
other studies reporting that long-term cryopreservation of human MNCs does 
not impair the MSC population leading to successful culture (Shen et al., 
2012) that proliferates and undergoes tri-lineage differentiation (Ginis et al., 
2012). 
In the absence of observable difference in cell adhesion responses due to 
SDF-1, we turned our attention to a second candidate molecule for control of 
cell adhesion and vascular support, Neuropilin 1. NRP1 is a VEGF co-
receptor that is thought to be critical for endothelial cell attachment and 
migration on fibronectin and angiogenesis (Valdembri et al., 2009) and 
vascular smooth muscle cell migration to PDGF-AA (Pellet-Many et al., 2011). 
NRP1 is also expressed on MSCs (Ball et al., 2010) yet it’s precise functions 
are still to be determined. Therefore we hypothesized that NRP1 would have 
a key role in cell adhesion responses and vascular support phenotype of 
MSCs. 
The assays developed and optimised during the first chapter were used to 
deterine the requirement of NRP1 in attachment, migration and vascular 
support MSCs.  By selectively knocking down NRP1 with siRNA the functional 
requirements of the protein could be analysed. NRP1 was important for 
 163 
attachment of MSCs to fibronectin, but not other extracellular matrix proteins, 
however it’s knockdown did not completely block cell attachment, indicating 
that other NRP1-independent pathways can partially rescue the defect. In 
addition, a significant decrease in chemotactic cell migration towards PDGF-
AA was seen and then in terms of a potential vascular support role of MSCs, 
knockdown of NRP1 impaired their ability to form tubule-like strucures and 
support a pre-exisiting endothelial network.  
The final chapter investigated the functional effect of upregulating NRP1. 
Previous reports have suggested that regulation of NRP1 is dependent on 
cell type with the same strategies resulting in polarizing effects. For example, 
some researchers found that NRP1 was increased by hypoxia in a HIF1 
dependant fashion (Ellis, 2006), whereas others found that hypoxia 
decreased NRP1 (Jogi et al., 2004). MSC studies in this thesis demonstrate 
that gene expression of NRP1 is down regulated following overnight culture in 
low oxygen conditions. Overnight stimulation with bFGF was shown to 
increase the expression of NRP1, in a proliferation-independent fashion. 
Stimulation with bFGF increased MSC adhesion to fibronectin in a NRP1 
dependent mechanism, but did not significantly impact on migration to PDGF-
AA. Preconditioning with bFGF increased the VEGF expression that has pro-
angiogenic effects. Results from this research could in future work move to in 
vivo models to identify if the in vitro improvements observed translate to 
enhanced therapeutic outcomes. 
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1.1 Implications for MSCs as a therapeutic candidate 
 
The development of cell therapy is unlike that of a pharmaceutical compound, 
for which the mechanism of action is known and can be robustly quantified. 
MSCs products have been developed by several companies are candidates 
in several companies targeting multiple indications including graft versus host 
disease and myocardial infarction. However, the precise mechanism is not 
fully characterised and potency assays for release are not yet standardized or 
widely available. This lack of knowledge is a current bottleneck to improving 
therapeutic outcome by means of bioprocess optimisation. The results from 
this study show that MSCs release a multitude of growth factors that have 
pro-angiogenic, cytoprotective and immunomodulatory properties, such as 
VEGF, IL-8, and HGF. If MSCs are preconditioned to have enhanced 
retention (a function of attachment and migration) at the psychological site of 
interest, alongside an improved cytokine release profile, this would 
synergistically improve the therapeutic outcome. 
Pharmacological preconditioning of MSC before therapeutic use is an 
effective strategy as a prerequisite to enhance MSC function. Other strategies 
include genetic manipulation to over express certain adhesion molecules, or 
secrete particular proteins. Preconditioning with bFGF can be incorporated as 
part of the manufacturing bioprocess and then removal of bFGF from the final 
product assessed as part of the post-processing quality control assessment 
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This study found that MSCs can interact directly with, and support a pre-
existing endothelial network. This is vital requirement post-infarction in a site 
in which not only are cardiomyocytes are lost but also the vascular network. 
In addition to indirect support, by paracrine factors such as VEGF, direct 
interactions would possibly facilitate support and regerenation of the 
diminished network by acting as a stromal support cell to the at risk vessels.  
There is much contention over the definitive identity of a MSC. At the start of 
the thesis the International Society of Cell Therapy (ISCT) defined a MSC as 
plastic adherent; CD105, CD73, and CD90 positive CD45, CD14 and CD19 
negative; with the ability to differentiate to osteoblasts, adipocytes and 
chondroblasts in vitro (Dominici et al., 2006). However, other studies have 
demonstrated similar characteristics in perivascular and fibroblast cells 
(Covas et al., 2008a).  Importantly, in vitro and in vivo models are unequivocal 
for clinical purposes. The assays developed in this thesis, particularly the 
endothelial support assay, offer a potential to correlate biological function in in 
vitro assays that more closely reflect physiologic environments. A new 
working proposal by the ISCT concentrates on the immunogenicity of MSCs 
such as response to IFN and TNFα, and indolamine 2,3 dioxygenase (IDO) 
release (Krampera et al., 2013). Defining a MSCs in this manner would not be 
suitable for an indication such as acute myocardial infarction where the 
proposed mechanism of action is vasculogenic and cytoprotective. During the 
entire study, MSCs were only characterized according to the original 2006 
ISCT criteria for continuity.   
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This study adds more evidence that MSCs are also similar to pericytes in 
function. The live cell staining in the network support assay clearly shows the 
MSCs bridging/communicating between the endothelial cells in a pericyte like 
fashion that was diminished when NRP1 was knocked down. Blocki et al, 
indicate that this may only represent a subpopulation of MSCs having a 
specialised role in vascular biology (Blocki et al., 2013) 
1.2 Heterogeneity of MSC isolations 
Throughout the thesis there was variability between the different MSC 
isolations, despite adoption of consistent isolation protocol and culture 
conditions. This was particularly evident in the protein release ELISAs 
whereby one donor isolation produced extremely high VEGF levels, up to 
three fold greater than that of other isolations. However higher release of one 
protein did not correspond to overall high protein release. Large donor 
variability accounted for differing response to bFGF stimulation. This is 
relevant to commercial scale manufacturing, because for an allogenic product 
an optimal MSC isolation should be chosen with the critical quality attributes 
indicated to achieve a greater clinical outcome. An isolation with increased 
engraftment and release of pro-vasculogenic cytokines, like VEGF, would be 
more suitable as a therapeutic candidate. On the other hand for autologous 
therapy, identifying patients whose cells do not produce a defined minimum 
threshold of growth factor levels or functional outputs would potentially 
provide a predictive measure of clinical failure and hence help to stratify the 
patient populations and improve the clinical success of cell therapies 
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Donor variation has been documented in several studies and Siegel et al 
identified HGF secretion as negatively correlated with expression of CD71, 
and CD140b (Siegel et al., 2013). Another study involving 17 donor isolations 
identified differences in growth rate and osteogenic potential (Phinney et al., 
1999). Inter-donor heterogeneity can be attributed to donor age and sex 
(Zhou et al., 2008).  
1.3 Conclusion 
Bone marrow derived stem cells are a suitable candidate for therapeutic use 
post AMI. This study developed suitable functional in vitro assays as a model 
to characterise these cells and investigate strategies to improve their 
retention and pro-vasculogenic capacity. The initial hypothesis that SDF-1 
would enhance these functions in MSCs and MNCs was unfounded, so an 
investigation into adhesion proteins, specifically NRP1, was investigated to 
ascertain it’s role. NRP1 was shown have an important role in adhesion and 
pro-vasulogenic function of MSCs. By upregulating NRP1 with bFGF, 
adhesion to fibronectin in hypoxic conditions that was significantly diminished 
was then rescued to that of normal oxygen tensions. These findings have for 
the potential to be translated for the successful improvement of a bioprocess 
of a cell therapy candidate for the prevention of heart failure. 
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1.4 Future work 
This investigation highlighted the importance of NRP1 in MSCs, and the 
potential for preconditioning by bFGF to be used to improve their biological 
function. The following investigations can take this work further: 
1. Development of the assays to validate the function of MSCs and use 
either as predictive tools to stratify and hence identify the most suitable 
patient candidates for autologous therapy or as identity/potency 
assays to provide a measure of key critical quality attributes 
2. Elucidation of the importance of biochemical pathways using 
knockdown or pre-stimualtion strategies 
3. In vivo MI model, or ex vivo langendorff, using bFGF preconditioned 
MSCs 
 
The cell therapy industry lacks appropriate release assays and validation of 
MSCs with no current standards in place. The assays I developed during this 
investigation can be further developed, and correlated to either surface 
marker expression, or protein secretion, which would then provide a surrogate 
measure of function. For instance, high adhesion may be associated with 
high integrin activation, or angiogenic response correlated to by VEGF 
secretion. To date, most release assays for MSCs involve the 
immunomodulatory function of MSCs that have more relevance for indications 
like GvHD. Biological release assays need to be developed that are more 
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relevant to mechanism of repair in AMI. In vivo in vitro correlation (IVIVC) is 
used for the development of small molecule drugs and provides a good 
predictive model for quality control that allows flexibility for process changes. 
The large donor-to-donor variability demonstrates how important it is develop 
potency assays that assess cellular function, not just their expression of 
arbitary surface markers or differentiation. In this addition, one limitation of 
this study was that although low oxygen was accounted for in the assays, 
other physiochemical conditions at injury sites such as pH changes due to 
oxidative stress were not accounted for. Therefore, implications of factors 
such as acidosis should be investigated to assess the impact on adhesion 
and migration. 
 
NRP1 has a multifaceted role being important for adhesion, migration and a 
vascular support function of MSCs. Identification of the downstream pathways 
NRP1 is involved with could lead to greater knowledge of mechanism of 
action of MSCs. The contribution of NRP1 to neovascularisation on other cell 
types, including endothelial cells, VSMCs and bone marrow mononuclear 
cells has been well documented, including it’s interacting with VEGFRs, 
PDGFRs, Semaphorin3a, and α5β1 (Fujisawa, 2002; Pellet-Many et al., 
2011; Valdembri et al., 2009; Zacchigna et al., 2008). Although, MSCs do not 
express VEGFRs, VEGF-A is channeled through PDGFRs (Ball et al., 2010). 
Co-immunopreciptation of NRP1 during adhesion to fibronectin and tubule 
formation would identity vital interactions. 
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In addition, although NRP1 knockdown had no effect on scratch wound 
closure on a fibronectin substrate, future immunoflourescence analysis would 
identify possible translocation of NRP1 to the leading edge of migration as 
postulated by Valdembri et al (Valdembri et al., 2009). This study showed the 
colocalisation of α5β1 integrin in trafficking vesicles and adhesion sites of 
endothelial cells. Investigation in MSCs using total internal reflection 
fluorescence (TIRF) would assess this interaction, via fluorescence 
resonance energy transfer (FRET), between α5β1 integrin and NRP1. 
 
MSCs preconditioned with bFGF demonstrated a novel way of improving 
engraftment and vascular support function in in-vitro assays replicating the 
infarct physiological site. This can be taken forward into in vivo models to 
identify the translational potential of this strategy. Initial studies would use the 
chick embryo chorioallantoic membrane (CAM) assay to demonstrate 
neovascularisation in vivo as a relatively rapid protocol to follow on from the 
tubule network assays developed in vitro on matrigel. To estimate attachment 
a Langendorrf model can be used to analyse the change efflux of cells 
transplanted over time either intracoronary or intramyocardial after 
preconditioning. A collaborating lab has shown the majority of MNCs to efflux 
the Langendorff heart 5 minutes after injection intracoronary (data not 
published). Further to results from these models, preconditioned MSCs vs 
control MSCs would then be used in vivo using a rat MI model after left 
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anterior descending (LAD) occlusion. To identify and quantify engrafted 
MSCs in situ hybridization would be used for the human Y chromosome. 
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